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Lisa Deng 
 
THE ROLE OF BRUTON’S TYROSINE KINASE AND PI3K p110δ IN MUTANT SHP2-INDUCED 
JUVENILE MYELOMONOCYTIC LEUKEMIA 
 
Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloproliferative 
neoplasm that lacks effective chemotherapies. Most commonly, patients have gain-of-
function (GOF) oncogenic mutations in SHP2, leading to hyperactivation of ERK and AKT 
and hyperproliferation of cells in response to granulocyte macrophage-colony 
stimulating factor (GM-CSF). Our lab previously showed that p110δ, the hematopoietic-
specific catalytic subunit of phosphoinositide 3-kinase, is a crucial mediator of mutant 
Shp2-induced GM-CSF hypersensitivity in vitro. 
We treated oncogenic Shp2-expressing mice with a p110δ inhibitor and showed 
that the strong effect our lab observed in vitro translated into reduced splenomegaly 
and prolonged survival in vivo. We investigated molecules potentially cooperating with 
p110δ signaling and discovered that Bruton’s tyrosine kinase (BTK) is 
hyperphosphorylated in GOF Shp2 myeloid cells. We used specific BTK and p110δ 
inhibitors to demonstrate that BTK cooperates with p110δ to hyperactivate Akt/Erk and 
to promote hyperproliferation. GOF Shp2-expressing mice treated in vivo with the drug 
combination targeting p110δ and BTK have significantly decreased splenomegaly and 
WBC counts. 
vi 
We also explored the mechanism of BTK signaling and hypothesized that B cell 
adaptor for PI3K (BCAP) mediated BTK upregulation of PI3K activity. In mutant Shp2 
macrophages, we observed BCAP phosphorylation specifically in the larger isoforms 
needed for PI3K activation, and BTK inhibition led to a dose-dependent reduction in this 
phosphorylation. We also demonstrated reduced interaction between BCAP and the 
PI3K regulatory p85α subunit bearing mutated SH2 domains. 
Finally, we investigated the effects of mutated DNA methyltransferase 3A 
(Dnmt3a) in conjunction with GOF Shp2. Double mutant mice quickly became moribund 
with pronounced splenomegaly and leukocytosis. There was an expansion of mature 
myeloid cells in the periphery and myeloid progenitors in the bone marrow, plus anemia 
with evidence of compensatory erythropoiesis in the spleen. 
Our findings show that the myeloproliferative neoplasm caused by GOF Shp2 is 
due to hyperactive p110δ, and this is further promoted by BTK, which forms a positive 
feedback loop with PI3K and BCAP, thus leading to more Akt/Erk hyperphosphorylation 
and more hyperproliferation in response to GM-CSF. The dual inhibition of p110δ and 
BTK represents a novel effective treatment strategy for JMML and other diseases 
induced by oncogenic Shp2. 
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Reuben Kapur, PhD, Co-Chair 
 
 
vii 
TABLE OF CONTENTS 
LIST OF TABLES...................................................................................................................xi 
LIST OF FIGURES................................................................................................................xii 
LIST OF ABBREVIATIONS..................................................................................................xvii 
CHAPTER ONE.....................................................................................................................1 
INTRODUCTION...................................................................................................................1 
 Juvenile Myelomonocytic Leukemia.......................................................................1 
 Protein Tyrosine Phosphatase Non-Receptor Type 11 (PTPN11), SHP2.................5 
 Phosphoinositide 3-kinase (PI3K)..........................................................................10 
 Bruton’s Tyrosine Kinase (BTK): Structure and Signaling......................................15 
 Bruton’s Tyrosine Kinase: Role in Malignancies and Pharmacologic Inhibition....19 
 B-cell adaptor for phosphoinositide 3-kinase (BCAP)...........................................23 
 DNA Methyltransferase 3A (DNMT3A).................................................................28 
 Summary and Significance....................................................................................31 
CHAPTER TWO..................................................................................................................37 
MATERIALS AND METHODS..............................................................................................37 
Materials...............................................................................................................37 
Plasmids....................................................................................................37 
Primers......................................................................................................38 
Mice..........................................................................................................38 
Antibodies.................................................................................................39 
Inhibitors...................................................................................................41 
viii 
Kits............................................................................................................41 
Methods................................................................................................................42 
Cell Culture................................................................................................42 
Retroviral Supernatant Production...........................................................43 
Retroviral Transduction of NIH3T3 cells....................................................43 
Cell Sorting................................................................................................43 
Generation of NIH3T3 cells expressing constructs of Shp2, p85α, and 
BCAP..........................................................................................................44 
Isolation of Total Cellular Protein Lysates.................................................44 
Immunoblot Analysis................................................................................44 
Immunoprecipitation................................................................................45 
[3H]-Thymidine Incorporation Assay.........................................................45 
Methylcellulose Colony-Forming Assay....................................................46 
In vivo drug treatment of mice.................................................................46 
Flow Cytometry Analysis...........................................................................46 
Complete Blood Counts............................................................................47 
Statistical Analysis.....................................................................................47 
CHAPTER THREE................................................................................................................48 
PHARMACOLOGIC INHIBITION OF PI3K p110δ REDUCES SPLENOMEGALY AND 
PROLONGS SURVIVAL IN MUTANT Shp2E76K-EXPRESSING MICE.......................................48 
 Introduction..........................................................................................................48 
 Results...................................................................................................................49 
ix 
 Discussion.............................................................................................................66 
CHAPTER FOUR.................................................................................................................68 
PHARMACOLOGIC INHIBITION OF BTK AND OF PI3K p110δ COOPERATE TO REDUCE 
GAIN-OF-FUNCTION MUTANT SHP2-INDUCED GM-CSF HYPERSENSITIVITY AND THE 
DEVELOPMENT OF MYELOID LEUKEMIA..........................................................................68 
 Introduction..........................................................................................................68 
 Results...................................................................................................................70 
 Discussion.............................................................................................................94 
CHAPTER FIVE...................................................................................................................97 
BCAP IS HYPERPHOSPHORYLATED AND CONNECTS BTK SIGNALING TO PI3K IN GAIN-   
OF-FUNCTION MUTANT SHP2-EXPRESSING MYELOID CELLS............................................97 
Introduction..........................................................................................................97 
 Results.................................................................................................................101 
 Discussion...........................................................................................................111 
CHAPTER SIX...................................................................................................................115 
MICE WITH COMBINED MUTANT Shp2D61Y AND DNMT3A HAPLOINSUFFICIENCY        
HAVE RAPID DEVELOPMENT OF MYELOPROLIFERATIVE NEOPLASM.............................115 
 Introduction........................................................................................................115 
 Results.................................................................................................................116 
 Discussion...........................................................................................................126 
CHAPTER SEVEN..............................................................................................................129 
DISCUSSION....................................................................................................................129 
x 
Overall Conclusions and Significance..................................................................134 
Future Directions................................................................................................139 
REFERENCES....................................................................................................................142 
CURRICULUM VITAE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
LIST OF TABLES 
Table 1.1: Diagnostic criteria for JMML..............................................................................2 
Table 2.1: Genotyping primers.........................................................................................38 
Table 2.2: Primary antibodies for immunoblot.................................................................39 
Table 2.3: HRP Secondary antibodies...............................................................................40 
Table 2.4: Immunoprecipitation antibodies.....................................................................40 
Table 2.5: Primary antibodies for flow cytometry............................................................40 
Table 2.6: Secondary antibodies.......................................................................................41 
Table 2.7: Inhibitors..........................................................................................................41 
Table 2.8: Kits....................................................................................................................41 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
LIST OF FIGURES 
Figure 1.1: Schematic diagram of the normal SHP2 mechanism of activation and the 
result of common oncogenic mutations.............................................................................7 
Figure 1.2: Schematic diagram of the functional domains and intramolecular  
interactions between a catalytic subunit and a regulatory subunit of PI3K.....................11 
Figure 1.3: Schematic diagram of the functional domains of Tec kinases, including 
BTK....................................................................................................................................17 
Figure 1.4: Schematic diagram of the signaling pathway of BTK in B cells.......................18 
Figure 1.5: Schematic diagram of the structure of BCAP..................................................25 
Figure 3.1: PI3Kδ inhibition in vivo decreases splenomegaly in Shp2E76K/+;LysMcre+ 
mice..................................................................................................................................51 
Figure 3.2: Time-limited PI3Kδ inhibition in vivo does not permanently correct GM-     
CSF hypersensitivity of bone marrow progenitors in Shp2E76K/+;LysMcre+ mice...............52 
Figure 3.3: PI3Kδ inhibition in vivo decreases Lin-Sca1+cKit+ progenitor cells in the      
bone marrow of Shp2E76K/+;LysMcre+ mice.......................................................................54 
Figure 3.4: PI3Kδ inhibition in vivo does not affect terminally differentiated 
hematopoietic cell populations in the bone marrow of Shp2E76K/+;LysMcre+ mice..........55 
Figure 3.5: PI3Kδ inhibition in vivo does not affect terminally differentiated 
hematopoietic cell populations in the spleen of Shp2E76K/+;LysMcre+ mice......................56 
Figure 3.6: PI3Kδ inhibition in vivo increases the terminally differentiated myeloid      
cells in the peripheral blood of Shp2E76K/+;LysMcre+ mice................................................57 
xiii 
Figure 3.7: PI3Kδ inhibition in vivo increases the mean fluorescent intensity of Mac1      
in the peripheral blood of Shp2E76K/+;LysMcre+ mice........................................................58 
Figure 3.8: PI3Kδ inhibitor-treated Shp2E76K/+;LysMcre+ mice have prolonged survival 
compared to vehicle-treated mice...................................................................................60 
Figure 3.9: Vehicle- and PI3Kδ inhibitor-treated Shp2E76K/+;LysMcre+ mice have a       
sharp increase in average peripheral blood WBC count prior to a cluster of deaths.......61 
Figure 3.10: Vehicle- and PI3Kδ inhibitor-treated Shp2E76K/+;LysMcre+ mice have no 
differences in degree of splenomegaly or leukocytosis when moribund.........................63 
Figure 3.11: Vehicle- and PI3Kδ inhibitor-treated Shp2E76K/+;LysMcre+ mice have no 
differences in terminally differentiated hematopoietic cell populations in the bone 
marrow when moribund...................................................................................................64 
Figure 3.12: Vehicle- and PI3Kδ inhibitor-treated Shp2E76K/+;LysMcre+ mice have no 
differences in terminally differentiated hematopoietic cell populations in the spleen 
when moribund................................................................................................................65 
Figure 4.1: BTK and PLCγ2 are hyperphosphorylated in gain-of-function mutant        
Shp2-expressing macrophages.........................................................................................72 
Figure 4.2: Inhibition of BTK and p110δ independently decrease BTK phosphorylation    
in a dose-dependent manner in gain-of-function mutant Shp2-expressing 
macrophages....................................................................................................................74 
Figure 4.3: Inhibition of BTK and p110δ independently decrease Akt and Erk 
phosphorylation in a dose-dependent manner in gain-of-function mutant Shp2-
expressing macrophages..................................................................................................75 
xiv 
Figure 4.4: Proliferation is cooperatively decreased by BTK and p110δ dual inhibition     
in bone marrow LDMNCs from Shp2E76K/+;LysMcre+ mice................................................77 
Figure 4.5: BTK and p110δ dual inhibitor-treated Shp2E76K/+;LysMcre+ mice show a    
trend towards prolonged survival compared to vehicle-treated and single agent-   
treated mice......................................................................................................................79 
Figure 4.6: Vehicle-, BTK inhibitor-, and p110δ inhibitor-treated Shp2E76K/+;LysMcre+  
mice have no differences in degree of splenomegaly or leukocytosis when    
moribund..........................................................................................................................80 
Figure 4.7: Dual inhibition of BTK and p110δ in vivo trends towards decreased 
splenomegaly in Shp2E76K/+;LysMcre+ mice.......................................................................83 
Figure 4.8: BTK and p110δ dual inhibition in vivo trends towards a reduction in 
peripheral blood WBC count in Shp2E76K/+;LysMcre+ mice................................................84 
Figure 4.9: BTK and p110δ dual inhibition in vivo trends towards increased terminally 
differentiated myeloid cells in the peripheral blood of Shp2E76K/+;LysMcre+ mice...........85 
Figure 4.10: BTK and p110δ dual inhibition in vivo decreases splenomegaly in 
Shp2E76K/+;LysMcre+ mice..................................................................................................87 
Figure 4.11: BTK and p110δ dual inhibition in vivo decreases peripheral blood WBC 
count in Shp2E76K/+;LysMcre+ mice....................................................................................89 
Figure 4.12: BTK and p110δ dual inhibition in vivo decreases Lin-Sca1+cKit+ progenitor 
cells in the bone marrow of Shp2E76K/+;LysMcre+ mice.....................................................90 
xv 
Figure 4.13: BTK and p110δ dual inhibition in vivo does not affect terminally 
differentiated hematopoietic cell populations in the bone marrow of Shp2E76K/+; 
LysMcre+ mice...................................................................................................................91 
Figure 4.14: BTK and p110δ dual inhibition in vivo does not affect terminally 
differentiated hematopoietic cell populations in the spleen of Shp2E76K/+;LysMcre+ 
mice..................................................................................................................................92 
Figure 4.15: BTK and p110δ dual inhibition in vivo increases terminally         
differentiated myeloid cells and decreases the B cells in the peripheral blood of 
Shp2E76K/+;LysMcre+ mice..................................................................................................93 
Figure 5.1: Schematic of proposed signaling pathway explaining the ability of BTK           
to activate Akt and Erk in Shp2E76K/+;LysMcre+ myeloid cells..........................................100 
Figure 5.2: BCAP phosphorylation is increased by GM-CSF stimulation specifically in     
the full-length isoforms in bone marrow-derived macrophages from Shp2E76K/+;  
LysMcre+ mice.................................................................................................................103 
Figure 5.3: BCAP phosphorylation is decreased by ACP-196 in a dose-dependent   
manner in bone marrow-derived macrophages from Shp2E76K/+;LysMcre+ mice...........105 
Figure 5.4: BCAP expression is increased in bone marrow-derived macrophages 
expressing Shp2E76K.........................................................................................................106 
Figure 5.5: Schematic of transduction strategy used to generate NIH3T3 cells   
expressing three proteins-of-interest: Shp2, p85α, and BCAP.......................................108 
Figure 5.6: BCAP interaction with p85α is decreased by mutagenesis of both SH2 
domains..........................................................................................................................110 
xvi 
Figure 6.1: Dnmt3a+/-;D61Y mice show splenomegaly and leukocytosis at the time          
of death...........................................................................................................................118 
Figure 6.2: Dnmt3a+/-;D61Y mice have increased Gr1+Mac1+ myeloid cells in the      
spleen at the time of death............................................................................................119 
Figure 6.3: Dnmt3a+/-;D61Y mice have increased Gr1+Mac1+ myeloid cells in the 
peripheral blood at the time of death............................................................................120 
Figure 6.4: Dnmt3a+/-;D61Y mice have decreased B cells and T cells in the periphery       
at the time of death........................................................................................................121 
Figure 6.5: Dnmt3a+/-;D61Y mice have increased GMPs and MEPs in the bone        
marrow at the time of death..........................................................................................123 
Figure 6.6: Dnmt3a+/-;D61Y mice have anemia as indicated by peripheral blood 
measurements immediately prior to euthanasia...........................................................124 
Figure 6.7: Dnmt3a+/-;D61Y mice have compensatory erythropoiesis in the spleen......125
xvii 
LIST OF ABBREVIATIONS 
ALL…………………………………………….…………………………………….Acute Lymphoblastic Leukemia 
AML…………………………………………………………………….…………………….Acute Myeloid Leukemia 
BCAP…………………………………………………………………………………………….B Cell Adaptor for PI3K 
BCR……………………………………………………………………………………….………………….B Cell Receptor 
BTK…………………………………………………………………………………………….Bruton’s Tyrosine Kinase 
CHIP........................................................Clonal Hematopoiesis of Indeterminate Potential 
CLL…………………………………………………………….…………………….Chronic Lymphocytic Leukemia 
CML…………………………………………………………..……………………Chronic Myelogenous Leukemia 
CMP……………………………………………………………..…………………….Common Myeloid Progenitor 
DNMT3A…………………………………………………………………………….….DNA Methyltransferase 3A 
EP………………………………...…………………………………………...........…………….Erythroid Progenitor 
FACS……………………………………………………………………………Fluorescence-Assisted Cell Sorting 
FBS…………………………………………………………………………………….………………Fetal Bovine Serum 
G-CSF………………………………………..…………………………Granulocyte-Colony Stimulating Factor 
GM-CSF…………………….……………………Granulocyte-Macrophage-Colony Stimulation Factor 
GMP………………………………………..……………………………..Granulocyte Macrophage Progenitor 
GVHD…………………………………………………………………………….………..Graft Versus Host Disease 
HSC……………………………………………………………………………………..…… Hematopoietic Stem Cell 
HSCT………………………………………………..………………………Hematopoietic Stem Cell Transplant 
IB……………………………………………………………………………………..…………………………..Immunoblot 
IP…………………………………………………………………………….………………………Immunoprecipitation 
xviii 
JMML……………………………………………………….………………Juvenile Myelomonocytic Leukemia 
LDMNC………………………………………………………………….…………Low-Density Mononuclear Cell 
LRP…………………………………………………………………………………….Lineage Restricted Progenitor 
LSK……………………………………………………………………………………………………….Lineage-Sca1+cKit+ 
MAPK…………………………………………………………..………………Mitogen-Activated Protein Kinase 
MCL……………………………………………………………………………………………..Mantle Cell Lymphoma 
M-CSF…………………………………………………………………Macrophage-Colony Stimulating Factor 
MEP…………………………………………………………..………..Megakaryocyte Erythrocyte Progenitor 
MFI………………………………………………………………………………..………Mean Fluorescent Intensity 
MPN……………………………………………………………………………………Myeloproliferative Neoplasm 
MDS……………………………………………………………………………………….Myelodysplastic Syndrome 
MPP……………………………..……………………………………………………………..Multipotent Progenitor 
MZL…………………………………………………………………………………………Marginal Zone Lymphoma 
PH……………………………………………………………………………………………………..Plekstrin Homology 
PI3K………………………………………………………………………………….....…Phosphoinositide 3-Kinase 
PKC……………………………………………………………………………….………………………..Protein Kinase C 
PLCγ2………………………………………………………………...…………………………….Phospholipase C γ2 
PTP........................................................................................Protein Tyrosine Phosphatase 
SCF……………………………………………………….…………………………………………………Stem Cell Factor 
S.D……………………………………….…………………………………………………………….Standard Deviation 
S.E.M…………………………………………………………………..………………..Standard Error of the Mean 
SH2………………………………………………………………………………………………………….Src Homology 2 
xix 
SYK…………………………………………………………………………………….…………Spleen Tyrosine Kinase 
TEC…………………………………………….Tyrosine Kinase Expressed in Hepatocellular Carcinoma 
TIR……………………………………………………………………………………………..…………Toll-IL-1 Receptor 
TLR………………………………………………………………………………………………..………Toll-like Receptor 
TPO……………………………………………………………………………………..………………….Thrombopoietin 
WBC………………………………………………………………………..……………………………..White Blood Cell 
WM……………………..……………………………………………………Waldenström’s Macroglobulinemia 
WT…………………….…………………………..…………………………………………………………………Wild Type 
XID…………………………………………………………………..…………………….X-linked Immunodeficiency 
XLA……………………………………………………………………………………X-linked Agammaglobulinemia 
YFP…………………………………………………………………………………………Yellow Fluorescent Protein 
 
 
1 
CHAPTER ONE 
INTRODUCTION 
Juvenile Myelomonocytic Leukemia 
Juvenile myelomonocytic leukemia (JMML) is an aggressive childhood 
myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN). It is rare, with an 
incidence of about 1-2 cases per million, and makes up 2-3% of all childhood leukemias 
(Hasle, Wadsworth 1999, Passmore, Chessells 2003). The disease affects infants and 
young children, with a median age of 2 years. The typical presentation is notable for 
fever, failure to thrive, hepatosplenomegaly, thrombocytopenia, high white blood cell 
(WBC) count, and increased monocytes in the peripheral blood with some myeloid 
precursor cells (Loh 2011). The proper diagnosis of JMML can be difficult due to the 
rarity of the disease and because the presenting features are also associated with viral 
infections, such as cytomegalovirus, human herpesvirus-6, or Epstein-Barr virus 
(Lorenzana, Lyons 2002, Manabe, Yoshimasu 2004, Moritake, Ikeda 2009, Prabhu, Gupta 
2010).  
JMML (along with a few other diseases) bears features of both a myelodysplastic 
syndrome (MDS) as well as a myeloproliferative neoplasm (MPN). Thus, in 2001, the 
World Health Organization (WHO) created a separate category of mixed MDS and MPN 
for those leukemias that have characteristics of both. The WHO classification of myeloid 
tumors was revised in 2008 (Tefferi and Vardiman 2008) and again in 2016 (Arber, Orazi 
2016), and the most up-to-date diagnostic criteria for JMML are listed in Table 1.1.  
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Table 1.1: Diagnostic criteria for JMML 
I. Clinical and hematologic features (all 4 features mandatory) 
 • PB monocyte count ≥1 × 109/L (normal range = 0.2-1.0x109/L) 
 • Blast percentage in PB and BM <20% 
 • Splenomegaly 
 • Absence of Philadelphia chromosome (BCR/ABL1 rearrangement) 
II. Genetic studies (1 finding sufficient) 
 • Somatic mutation in PTPN11 or KRAS or NRAS (germ line mutations must be 
excluded) 
 • Clinical diagnosis of NF1 or NF1 mutation 
 • Germ line CBL mutation and loss of heterozygosity of CBL in BM and/or PB 
III. For patients without genetic features, besides the clinical and hematologic 
features listed under I, the following criteria must be fulfilled: 
 • Monosomy 7 or any other chromosomal abnormality or at least 2 of the 
following criteria: 
  • Hemoglobin F increased for age 
  • Myeloid or erythroid precursors on PB smear 
  • GM-CSF hypersensitivity in colony assay 
  • Hyperphosphorylation of STAT5 
Adapted from (Arber, Orazi 2016) 
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Patients over 4 years of age presenting with elevated fetal hemoglobin greater than 15% 
and platelets less than 33,000/uL fall into a poor prognosis category (Chan, Cooper 
2009). For unknown reasons, there is a male predominance in JMML with a male to 
female ratio of 2.5:1 (Emanuel 2008). 
The majority of JMML patients have mutations in the genes PTPN11 (35%), KRAS 
or NRAS (35%), NF1 (10%) and CBL (10%) (Chan, Cooper 2009, Hasle 2016). Of these, 
somatic PTPN11 mutations tend to be the most aggressive and warrant immediate 
allogeneic hematopoietic stem cell transplant (HSCT). Conversely, a “watchful waiting” 
plan may be appropriate for cases with germline PTPN11 and CBL mutations, and some 
somatic NRAS mutations, as cases with these mutations progress slowly and may even 
spontaneously resolve (Hasle 2016). However, these driver mutation classifications are 
not reliable indicators of disease aggressiveness. In recent years, whole-exome 
sequencing has been used to explore genomic differences between the aggressive and 
mild cases of JMML, and to identify previously unknown mutations involved in disease 
pathogenesis. Results from these studies provide additional information to resolve 
difficult decisions regarding treatment and offer strategies for developing novel 
therapies.  
Sakaguchi et al. discovered from a cohort of 92 JMML patients that the genes 
SETBP1 and JAK3 are commonly involved as secondary somatic mutations (8% and 11%, 
respectively), especially in the presence of mutated PTPN11 or NF1, and confer a much 
worse prognosis (Sakaguchi, Okuno 2013). Stieglitz et al. reported on a technique called 
droplet digital polymerase chain reaction that can be used to detect SETBP1 mutations 
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in rare leukemia subclones at the time of diagnosis, thus identifying a much larger 
percentage of patients (30.3%) that harbor this aggressive form of JMML and should 
receive immediate HSCT (Stieglitz, Troup 2015). Furthermore, mutations in epigenetic 
modifiers were recently reported to be more common than previously believed, with 
the gene DNMT3A in particular found to be mutated in 3 of 100 JMML patients 
(Stieglitz, Taylor-Weiner 2015). These recent efforts reflect the drive to understand the 
underlying molecular mechanisms of JMML in an attempt to develop more personalized 
treatment plans and more targeted therapies for patients. 
The current chemotherapeutic treatments for patients with JMML lack efficacy. 
Bergstrasser et al. demonstrated this conclusion by performing a retrospective study 
comparing various combination therapies, including interferon-alpha, etoposide, 
cytarabine, and 6-mercaptopurine/6-thioguanine. Importantly, in their analysis the 
authors standardized the definitions of disease regression using WBC count, platelet 
count, liver size, and spleen size. Although they found that certain agents resulted in 
partial responses, they concluded that all responses were transient and without 
improvement in overall survival (Bergstraesser, Hasle 2006). Because intensive 
chemotherapy is unable to significantly prolong survival, the only effective treatment is 
allogeneic HSCT, preferably from an HLA-matched donor, as the risk of relapse is higher 
if using unmatched donor HSCT or fetal cord blood. Cyclosporine-A, with or without 
methotrexate, is administered to prevent graft vs. host disease (GVHD), but may need to 
be reduced or discontinued to allow the graft vs. leukemia effect to occur. Because total 
body irradiation hampers this antileukemic effect and can lead to risk of infections, it is 
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recommended to be avoided as part of the conditioning regimen (Locatelli, Nöllke 
2005). 
Despite undergoing the aggressive intervention of allogeneic HSCT, about 50% of 
recipients will relapse with JMML, which is much higher than the 7% relapse rate seen in 
chronic myelogenous leukemia (CML) (Speck, Bortin 1984). Locatelli et al. reported that 
a cohort of 100 JMML patients, who were all conditioned identically with busulfan, 
cyclophosphamide, and melphalan, had a 64% 5-year overall survival and a 52% 5-year 
event-free survival. Thirty-four patients relapsed after HSCT at a median time of 6 
months, and twenty-one patients had disease progression that resulted in death 
(Locatelli, Nöllke 2005). For patients who relapse, a second allogeneic HSCT with 
reduced amounts of immunosuppression has been recommended, but this intervention 
only rescues an additional one third of patients (Chang, Jou 2004, Inagaki, Fukano 2013, 
Yoshimi, Mohamed 2007). The ultimate cause of death is either transformation into 
acute myeloid leukemia (AML) or, more commonly, peripheral organ infiltration by 
monocytes and macrophages, leading to pulmonary failure, diarrhea, bleeding, and/or 
infection (Emanuel 2008). 
 
Protein Tyrosine Phosphatase Non-Receptor Type 11 (PTPN11), SHP2 
 PTPN11 is the most commonly mutated gene in JMML at 35% of all cases. It 
encodes for SHP2, a non-receptor protein tyrosine phosphatase that is a positive 
regulator of many signaling pathways, including PDGFR, IRS1, JAK-STAT, and PI3K/AKT, 
among others (Mohi and Neel 2007, Ronnstrand, Arvidsson 1999). The protein structure 
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is notable for its N-Src homology 2 (N-SH2) domain and the protein tyrosine 
phosphatase (PTP) domain, which interact with each other to maintain the inactive 
conformation. Peptides with phospho-tyrosine residues bind to the N-SH2 and C-SH2 
domains, causing SHP2 to open into its active form and allowing the PTP domain access 
to a substrate. Mutations in amino acid residues within these domains that preclude the 
folding of SHP2 into its inactive conformation lead to constitutive phosphatase 
activation, making PTPN11 a bona fide proto-oncogene (Figure 1.1) (Chan and Feng 
2007). Mutant PTPN11 now has a well-established role as an oncogene in various 
leukemias such as JMML, AML, MDS, and acute lymphoblastic leukemia (Kratz, 
Niemeyer 2005, Loh, Reynolds 2004, Loh, Vattikuti 2004, Tartaglia, Martinelli 2004, 
Tartaglia, Niemeyer 2003), and in some solid tumors (Bentires-Alj, Paez 2004, Loh, 
Martinelli 2005, Martinelli, Carta 2006). SHP2’s major role in promoting cancer lies in 
part in its ability to activate RAS-MAPK signaling, either by dephosphorylating (and thus 
inactivating) the RAS inhibitor, RAS-GAP, or dephosphorylating the SRC inhibitor, CSK, 
thus leading to more SRC activity and subsequent RAS activation (Chan and Feng 2007). 
 A recently published paper demonstrated that mutant SHP2 plays an oncogenic 
role even when expressed only in the bone marrow microenvironment. Dong et. al 
observed that mice developed myeloid leukemia when mutant Ptpn11 was conditionally 
expressed only in bone marrow mesenchymal stem/progenitor cells using Nestin 
promoter-directed Cre expression. The authors also found that these mice developed a 
donor-derived myeloproliferative neoplasm after being transplanted with WT bone 
marrow cells (Dong, Yu 2016). This is the first study demonstrating that bone marrow  
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Figure 1.1: Schematic diagram of the normal SHP2 mechanism of activation and the 
result of common oncogenic mutations 
(A) The closed, inactive state of SHP2 is stabilized by hydrophobic interactions between 
its N-SH2 and PTPase domains. When phospho-tyrosine residues bind to the N-SH2 and 
C-SH2 domains of SHP2, it transforms into its open, active conformation. This allows the 
PTPase domain to access and dephosphorylate a substrate. (B) Common oncogenic 
mutations in SHP2, found in the N-SH2 domain or in the PTPase domain, disrupt the 
interaction between the N-SH2 and PTPase domains. This destabilizes the inactive state 
and leads to SHP2 adopting a constitutively active conformation (adapted from (Chan 
and Feng 2007)). 
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niche-restricted expression of Shp2E76K is capable of inducing abnormal function of WT 
bone marrow cells and implies an explanation for the poor engraftment and relapse 
seen in JMML patients following allogeneic HSCT. The commonly observed resurgence 
of the JMML leukemic clone following transplantation may be due to the inability of the 
normal donor HSCs to engraft and remain in a quiescent state in the aberrant bone 
marrow microenvironment, permitting outgrowth of residual leukemic cells and thus 
patient relapse. 
In addition to malignancies, activating mutations of PTPN11 in the germline are 
found in 50% of patients with the autosomal dominant disorder Noonan syndrome (NS). 
This developmental disorder occurs in 1 in 1000-2500 live births and is characterized by 
growth retardation, dysmorphic facial features, congenital heart defects, and skeletal 
abnormalities (Tartaglia and Gelb 2005, Tartaglia, Mehler 2001). Noonan syndrome 
patients with PTPN11 mutations are more susceptible to developing hematologic 
disorders, including JMML. The form of JMML affecting NS patients can follow an 
aggressive clinical course, but may also regress spontaneously, indicating that NS 
patients may not need immediate allogeneic HSCT intervention despite bearing a 
mutation in PTPN11 (Kratz, Niemeyer 2005). This more indolent clinical course may be 
due to the particular germline PTPN11 mutations commonly found in NS patients 
(N308S, A922G), which although located in the N-SH2 and PTP domains, are less 
activating than the somatic mutations most frequently found in JMML (D61Y, E76K) 
(Schubbert, Lieuw 2005, Tartaglia, Kalidas 2002). In a cohort of 91 NS patients and 27 
JMML/MDS/AML patients, the most prevalent PTPN11 mutations occurred at the N-SH2 
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residues E76 (33%) and D61 (26%), and the residue N308 (36%) in the PTPase domain 
(Schubbert, Lieuw 2005). Noonan syndrome with multiple lentigines (NSML), previously 
known as LEOPARD syndrome, is a similar disorder to NS characterized by Lentigines, 
Electrocardiogram abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal 
genitalia, Retardation of growth, and Deafness. It is interesting that both NS and NSML 
patients have similar clinical phenotypes, because NSML is caused by loss of 
phosphatase function mutations occurring in the PTP domain of SHP2 (Qiu, Wang 2014).  
As previously stated, aberrant SHP2 activation has been established as a driver of 
various leukemias. Attempts to inhibit this upregulated signaling by direct targeting of 
SHP2 have been met with largely disappointing results. The difficulty lies in selective 
binding of small molecule inhibitors to the catalytic site, because this area is highly  
conserved among protein phosphatases (Barr 2010). Although there have been some 
promising preclinical results in vitro and in vivo, these successes have not held up in 
humans (Butterworth, Overduin 2014, Pathak and Yi 2001, Yi, Elson 2011). To bypass the 
non-specificity hurdles, more recent efforts have focused on creating allosteric 
inhibitors, which can be directed at unique domains of SHP2 to decrease the active site’s 
affinity for substrate. SHP099 and IACS-13909 are two examples of small molecule 
allosteric SHP2 inhibitors that were recently developed (Chen, LaMarche 2016, Garcia 
Fortanet, Chen 2016). Also, a high-throughput compound screen identified 
benzothiazolopyrimidones as a chemical scaffold that interacts with the C-SH2 and PTP 
domains to allosterically stabilize SHP2’s autoinhibited conformation (LaRochelle, Fodor 
2017). However, these allosteric inhibitors have yet to be proven effective against 
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constitutively active leukemogenic SHP2, which is unable to sustain the self-inhibitory 
state. Therefore, until effective SHP2 drug inhibitors have been developed and tested, it 
is reasonable to also focus efforts on molecular targets downstream of SHP2. 
 
Phosphoinositide 3-kinase (PI3K) 
One particular downstream effector that has been identified as an important 
player in SHP2 signaling is phosphoinositide 3-kinase (PI3K). Class Ia PI3K is a lipid kinase 
that acts on a component of the plasma membrane, phosphatidylinositol-4,5-
bisphosphate [PI(4,5)P2], to phosphorylate it into phosphatidylinositol-3,4,5-
trisphosphate [PI(3,4,5)P3] (Cantley 2002). Signaling kinases that contain Plekstrin 
Homology (PH) domains are recruited to the membrane by direct binding to this 
PI(3,4,5)P3 phosphorylated lipid product. These proteins then become activated and can 
signal to their downstream effectors (Cantley 2002, Wang and Shaw 1995). One 
noteworthy example of PH domain protein signaling is PDK1 and its direct downstream 
target AKT, both of which contain PH domains and are thus brought into close proximity 
of each other by PI(3,4,5)P3. The phosphorylation of AKT by PDK1 allows key signaling 
downstream to promote cell survival and growth (Lawlor and Alessi 2001). Another PH 
domain-containing protein is Bruton’s tyrosine kinase (BTK), which will be further 
discussed below.  
Structurally, class Ia PI3K is a heterodimer made up of one of three catalytic 
subunits (p110α, p110β, or p110δ) and a regulatory subunit (p85α or its splice variants  
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Figure 1.2: Schematic diagram of the functional domains and intramolecular 
interactions between a catalytic subunit and a regulatory subunit of PI3K 
PI3K is a heterodimer made up of a regulatory subunit (p85) and a catalytic subunit 
(p110). The regulatory subunit has two Src Homology-2 domains (N-SH2 and C-SH2), 
which interact with phospho-tyrosine residues; an inter-SH2 (iSH2) in between the two 
SH2 domains, which interacts with the catalytic subunit; a Src Homology-3 (SH3) 
domain, which interacts with proline-rich domains; and a Breakpoint clustered 
Homology (BH) domain. The catalytic subunit contains an Adapter-Binding Domain 
(ABD), which mediates the major interaction with the regulatory subunit; a Ras-Binding 
Domain (RBD), where Ras binds and promotes the activation of PI3K; a protein-kinase-C 
homology-2 (C2) domain, which mediates interactions with lipid membranes; and the 
Kinase domain, which performs the lipid phosphorylation activity (adapted from (Zhao 
and Vogt 2008)). 
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p55α and p50α, p85β, or p55γ) (Vanhaesebroeck, Guillermet-Guibert 2010). Each of the 
p110 subunits are encoded by a separate gene (PIK3CA for p110α, PIK3CB for p110β, 
and PIK3CD for p110δ) and the regulatory subunits are encoded by PIK3R1 (p85α, p55α, 
p50α), PIK3R2 (p85β), and PIK3R3 (p55γ) (Jean and Kiger 2014). The regulatory subunits 
contain an N-terminal and a C-terminal Src homology 2 domain (N-SH2 and C-SH2), 
between which lies an intervening region (iSH2). The iSH2 region binds to the N-terminal 
adaptor-binding domain (ABD) on the p110 catalytic subunit, thus allowing constitutive 
interaction between the two subunits (Figure 1.2). This interaction stabilizes the 
catalytic subunits and protects them from degradation (Fruman 2010). p85 also acts as 
an adaptor whereby the SH2 domains recruit the PI3K complex to phosphorylated 
tyrosine residues on activated signaling proteins, normally downstream of receptor 
tyrosine kinases (Vadas, Burke 2011). 
As mentioned above, PI3K has roles in the regulation of cell proliferation, 
growth, and survival. Therefore, it is unsurprising that upregulated PI3K signaling is 
found in numerous human cancers. Most frequently, PI3K signaling is aberrantly 
upregulated due to an oncogenic upstream effector or due to loss of activity of 
phosphatase and tensin homolog (PTEN), the functional antagonist of PI3K (Luo, 
Manning 2003). Although less common, the genes encoding the p110 subunits 
themselves can also play important roles in human cancer when they become 
constitutively active or are erroneously overexpressed. The p110α gene, PIK3CA, is one 
of the most commonly mutated oncogenes in breast cancer (Lawrence, Stojanov 2014) 
and mutations in PIK3CD lead to activated PI3Kδ syndrome (APDS), a primary 
13 
immunodeficiency syndrome which sharply increases the risk of developing B cell 
lymphomas (Crank, Grossman 2014, Kracker, Curtis 2014). Thus, PI3K is recognized as a 
promising drug target, with various inhibitors already developed and tested preclinically 
and clinically. For example, the p110δ inhibitor umbralisib is currently in clinical trials for 
relapsed/refractory Hodgkin and non-Hodgkin lymphoma following favorable preclinical 
data and phase II trials (Deng, Lipstein 2017). Duvelisib is a p110δ and p110γ inhibitor 
that has shown activity against chronic lymphocytic leukemia (CLL) cells in vitro and is 
now in a phase III trial for treatment of relapsed/refractory CLL (Balakrishnan, Peluso 
2015, Flinn, Jäger 2014). FDA approval was recently granted to copanlisib (Aliqopa), an 
inhibitor of the α- and δ-isoforms of PI3K, for the treatment of patients with relapsed 
follicular lymphoma (Dreyling, Morschhauser 2017). Finally, a specific p110δ inhibitor, 
idelalisib (Zydelig), has been FDA approved for use in patients with relapsed chronic 
lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma, and small lymphocytic 
lymphoma (Furman, Sharman 2014, Gopal, Kahl 2014). 
Pan-PI3K inhibitors, such as wortmannin and LY294002, although quite useful as 
research tools, have little clinical usefulness due to poor selectivity and thus low 
tolerability (Gharbi, Zvelebil 2007, Liu, Shreder 2005). However, isoform-specific 
inhibitors have proven more successful because a higher efficacy-to-toxicity ratio can be 
achieved. Of the catalytic subunits, p110δ in particular has been identified as a good 
target for leukemia therapies because its expression is predominantly in hematopoietic 
cells, whereas p110α and p110β are ubiquitously expressed (Zhao and Vogt 2008). A 
genetic mouse model with mutated kinase inactive p110δ (p110δD910A/D910A) 
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demonstrated that the complete loss of p110δ activity does not cause lethality or 
developmental defects except for reduced numbers and function of B cells, and of T 
cells to a lesser extent (Okkenhaug, Bilancio 2002). These findings further strengthen 
the rationale for targeting p110δ, as there would be minimal side effects upon 
inhibition. 
The majority of p110δ research has been performed in lymphoid malignancies, 
and in 2014 idelalisib (previously called CAL-101 and GS-1101) became the first PI3K 
inhibitor approved by the FDA for three B cell neoplasms: relapsed/refractory CLL (in 
combination with the anti-CD20 antibody rituximab), relapsed follicular lymphoma, and 
relapsed small lymphocytic lymphoma (Yang, Modi 2015). Idelalisib is a potent and 
specific p110δ inhibitor, with an IC50 of 19nM and 110-fold selectivity over p110γ, 210-
fold over p110β, and 453-fold over p110α (Somoza, Koditek 2015). Although the focus 
has mainly been in lymphoid diseases, recently there has been growing evidence that 
p110δ also plays an important role in myeloid cell lineages as well. For instance, the 
p110δ isoform was found to be consistently overexpressed in AML patient blast cells 
(Sujobert, Bardet 2005). Furthermore, in a mouse model of JMML bearing the gain-of-
function Shp2 mutation, D61Y, p110δ activity was shown to be vital for in vitro 
hyperproliferation of bone marrow low-density mononuclear cells, hyperactivation of 
the downstream cell growth/survival regulators Akt and Erk, and progenitor 
hypersensitivity to GM-CSF. Goodwin et al. demonstrated these findings using mice 
bearing genetic inactivation of Pik3cd (p110δD910A/D910A), the p110δ inhibitor, GS-9820, 
against Shp2D61Y-expressing murine cells, and idelalisib against primary leukemia cells 
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from JMML patients (Goodwin, Li 2014). Therefore, p110δ inhibitors have recently 
gained relevance for JMML and other myeloid leukemias in addition to lymphoid 
malignancies. 
 
Bruton’s Tyrosine Kinase (BTK): Structure and Signaling 
 Bruton’s tyrosine kinase (BTK) is another Plekstrin Homology domain-containing 
signaling kinase activated downstream of PI3K. BTK plays a key role in B cell receptor 
(BCR) signaling as evidenced by the immunodeficiency disease X-linked 
agammaglobulinemia (XLA), where patients have inherited mutations causing loss of 
BTK function. In affected males, there is an almost complete lack of mature B cells and 
serum immunoglobulins, making these patients susceptible to severe and recurrent 
bacterial infections. The immune cell developmental defects are limited to the B cell 
lineage, and do not cause deficiencies in T cells or myeloid cells. BTK was identified in 
1993 as the non-receptor protein tyrosine kinase responsible for XLA, so it has long been 
known to be a key player in regulating B cell proliferation and survival (Hendriks, Bredius 
2011, Tsukada, Saffran 1993, Vetrie, Vorechovsky 1993). There also exists a mouse 
strain with a point mutation in Btk, which causes the disease X-linked immunodeficiency 
(XID). Interestingly, XID mice have a somewhat less severe phenotype than humans 
affected with XLA (Rawlings, Saffran 1993, Thomas, Sideras 1993). 
 BTK is one of the members of the TEC kinase family, which also includes four 
other non-receptor tyrosine kinases: tyrosine kinase expressed in hepatocellular 
carcinoma (TEC), interleukin-2-inducible T cell kinase (ITK), resting lymphocyte kinase 
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(RLK) and bone marrow-expressed kinase (BMX) (Bradshaw 2010). The TEC family 
members are expressed in various cell types, with ITK and RLK expressed in T cells, TEC 
expressed in B and T cells, and BMX expressed in myeloid cells. Loss of TEC in mice does 
not cause any apparent immunological defects, but the combined deletion of both Tec 
and Btk results in a more severe B cell development arrest than that seen in Btk-/- mice. 
Therefore, it has been postulated that TEC is able to compensate for BTK in mice to a 
certain extent, lessening the B cell phenotype seen in XID mice (Ellmeier, Jung 2000). 
The structure of BTK contains multiple domains that allow it to function as a key 
signaling molecule. It contains the SRC homology domains SH2 and SH3, a catalytic 
domain, the aforementioned PH domain, and a TEC homology domain (Figure 1.3) 
(Bradshaw 2010). BTK is predominantly cytoplasmic and requires PH domain-to-
PI(3,4,5)P3 binding in order to be recruited to the membrane. BTK is activated 
downstream of B cell receptors after antigen binding and activation. To become active, 
BTK first associates with the membrane, and is then phosphorylated at tyrosine 551 
(Y551) by spleen tyrosine kinase (SYK) or a SRC family kinase, which leads to 
autophosphorylation of Y223 (Park, Wahl 1996, Rawlings, Scharenberg 1996).  
Once phosphorylated, BTK is stimulated to signal to its downstream targets, and 
research has focused mainly on its role in BCR signaling. The major known function of 
BTK is direct phosphorylation of phospholipase C γ2 (PLCγ2) at Y753 and Y759, leading 
to the activation of PLCγ2 lipase activity (Kim, Sekiya 2004). PLCγ2 then cleaves PI(4,5)P2 
into the two second messengers inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 
goes on to regulate intracellular Ca2+ levels, while DAG promotes the activation of  
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Figure 1.3: Schematic diagram of the functional domains of Tec kinases, including BTK 
BTK, a member of the Tec kinase family, contains multiple functional domains. The 
Plekstrin Homology (PH) domain is needed for binding to PI(3,4,5)P3 at the plasma 
membrane; the Tec homology (TH) domain is an extension of the PH domain; the Src 
Homology-3 (SH3) domain, which has Y223, is the site of autophosphorylation; the Src 
Homology-2 (SH2) domain; and the kinase domain, which has Y551, is the residue 
phosphorylated by SYK after BCR cross-linking (adapted from (Bradshaw 2010)). 
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Figure 1.4: Schematic diagram of the signaling pathway of BTK in B cells 
BTK is phosphorylated downstream of B cell receptors (BCR) after antigen stimulation 
and cross-linking. The activated BTK, which is recruited to PI(3,4,5)P3 in the membrane, 
directly phosphorylates PLCγ2. PLCγ2 then hydrolyzes PI(4,5)P2 into IP3 and DAG. IP3 
leads to the release of intracellular calcium and DAG promotes the activation of PKC. 
Both of these events increase ERK activity, and thus cell survival and proliferation. Solid 
arrows indicate activation by direct interactions; dotted arrows indicate indirect 
activation. 
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protein kinase C (PKC) and then ERK, which is also dependent on RAS signaling (Figure 
1.4) (Hashimoto, Okada 1998). Beyond its role downstream of the B cell receptor, BTK is 
also involved in chemokine receptor and toll-like receptor signaling in B cells. 
Interestingly, there has been some evidence that BTK can act independently of its kinase 
activity. As an adaptor protein, BTK can recruit phosphatidylinositol 4-phosphate 5-
kinase (PI4P5K) to the plasma membrane, which promotes the production of PI(4,5)P2 
from phosphatidylinositol 4-phosphate. This forms a positive-feedback loop whereby 
BTK enhances the generation of the PI(3,4,5)P3 needed for its own activation (Saito, 
Tolias 2003). 
 
Bruton’s Tyrosine Kinase: Role in Malignancies and Pharmacologic Inhibition 
 BTK is expressed in various B cell leukemias and lymphomas which, combined 
with the isolated effects to the B cell lineage upon complete loss of BTK, makes it an 
attractive target for inhibition. The first rationally designed small-molecule inhibitor of 
BTK, LFM-A13, was described in 1999 to have anti-leukemic activity in vitro (Mahajan, 
Ghosh 1999). However, the first BTK inhibitor to enter clinical trials was ibrutinib (PCI-
32765, trade name Imbruvica), and it went on to receive accelerated FDA-approval for 
the treatment of patients with relapsed mantle cell lymphoma (MCL) in 2013 (Dreyling, 
Jurczak 2016). In 2014, ibrutinib approval was expanded to include patients with 
relapsed chronic lymphocytic leukemia (CLL) following the success of the RESONATE 
trial, and then for use as first-line CLL treatment in 2016 based on the results of the 
RESONATE-2 study (Barr, Robak 2016, Burger, Tedeschi 2015, Byrd, Brown 2014). It was 
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also approved for the treatment of Waldenström’s macroglobulinemia (WM) in 2015, 
relapsed/refractory marginal zone lymphoma (MZL) in January 2017, and chronic graft 
versus host disease (GVHD) in August 2017 (Dimopoulos, Trotman 2017, Miklos, Cutler 
2017, Noy, Vos 2016). Ibrutinib has also been shown to improve overall response rate 
when used in combination with other agents, namely with ofatumumab in CLL 
(Jaglowski, Jones 2015), and with rituximab in high-risk CLL (Burger, Keating 2014) and 
relapsed/refractory MCL (Wang, Lee 2016). 
Part of ibrutinib’s success as an anti-tumor agent is due to activity beyond its 
role in BCR signaling. BTK is also important for B cell chemokine receptor signaling 
involving CXCR4. CXC-chemokine ligand 12 (CXCL12), the ligand for CXCR4, activates 
BTK, and BTK plays a major role in normal B cell trafficking and tissue homing (de Gorter, 
Beuling 2007). As such, BTK signaling promotes CLL cell migration to the proliferative 
centers in lymph nodes and spleens as well as retention in this protective 
microenvironment. In fact, there is a phenomenon of ibrutinib-induced lymphocytosis in 
CLL patients, as inhibition of BTK disrupts multiple pathways needed for CLL cell 
retention in protective microenvironments and results in rapid mobilization into the 
peripheral circulation (Byrd, Furman 2013).  
Despite ibrutinib’s impressive performance against multiple B cell diseases, it is 
not without its problems. Ibrutinib’s mechanism of action involves covalent binding to 
cysteine 481 (C481) inside BTK’s ATP binding pocket, but it also has off-target 
irreversible binding to epidermal growth factor receptor (EGFR), TEC, ITK, and T-cell X 
chromosome kinase (TXK) (Honigberg, Smith 2010), which can lead to undesirable 
21 
adverse events of increased bleeding and atrial fibrillation. Furthermore, although XLA 
patients have abnormalities limited to the B cell lineage, ibrutinib administration leads 
to the broader chemotherapy toxicities of neutropenia, anemia, thrombocytopenia, 
diarrhea, nausea, rash, bruising, fatigue, pyrexia, and hemorrhage (Khan, Gibbons 2017). 
Surprisingly because of the irreversible inhibition of BTK and the immunodeficiency 
phenotype of XLA patients, the amount of immunosuppression actually decreases over 
time with continued use of ibrutinib. A clinical study showed that the reduction in 
average infection rate of patients treated with ibrutinib could be explained by a 
corresponding rise in IgA levels (Byrd, Furman 2013). As mentioned previously, two 
more serious complications of ibrutinib involve the development of atrial fibrillation and 
bleeding, indicating that consideration must be taken prior to giving patients 
anticoagulation or performing surgery (Yun, Vincelette 2017). 
Several second-generation inhibitors have been developed that are improved 
upon ibrutinib. Acalabrutinib, ONO/GS-4059, and BGB-3111 are all irreversible BTK 
inhibitors with higher selectivity for BTK than other kinases such as EGFR, ITK, and 
others (Sarkissian and O'Brien 2017). Of these, FDA approval was recently granted to 
acalabrutinib (ACP-196, trade name Calquence) for use in patients with relapsed 
mantle cell lymphoma based on results of the ACE-LY-004 phase II trial (NCT02213926). 
Like ibrutinib, ACP-196 also covalently binds to C481, and although the IC50 of ACP-196 
for BTK is 3-fold greater than that of ibrutinib, its IC50 for other kinases is much higher. 
ACP-196 also has better pharmacologic features, namely improved plasma exposure, 
more rapid oral absorption, and a shorter half-life. These compound characteristics 
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allow more frequent dosing and continuous BTK binding while eliciting fewer toxic 
effects from off-target binding to other kinases (Byrd, Harrington 2016). These 
improvements in acalabrutinib are highly notable because the development of side 
effects is the most common reason that patients discontinue ibrutinib treatment. The 
phase I/II trial results of 61 relapsed/refractory CLL patients revealed that prolonged 
and continuous ACP-196 treatment led to minor adverse events that self-resolved over 
time with few patients developing more serious adverse events (diarrhea, arthralgia, 
pyrexia, fatigue, hypertension) and only 1 patient experiencing disease progression 
(Byrd, Harrington 2016). A phase III trial comparing ACP-196 to ibrutinib in 
relapsed/refractory CLL is currently recruiting patients to evaluate progression-free 
survival (NCT02477696). 
In addition to toxicity, another problem that can occur under ibrutinib treatment 
is the development of resistance by the malignant cells. This can occur by either a 
substitution of cysteine to serine at the BTK binding site, leading to reversibility of 
ibrutinib binding, or by acquiring activating mutations in PLCγ2 (Woyach, Furman 2014). 
Second-generation inhibitors like ACP-196 do not circumvent this problem, so an 
alternate strategy is to target other molecules in the signaling pathway, such as p110δ, 
PLCγ2, and/or others. 
Because BTK’s major function was found to be downstream of BCR signaling, 
prior research on BTK has largely focused on its role in normal B cell development and in 
B cell malignancies. However, despite the apparently B cell-restricted phenotype in XLA, 
BTK is expressed in all hematopoietic cell types except for T lymphocytes and plasma 
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cells (Smith, Baskin 1994), so it is likely to function in the signaling of the other cell types 
as well. Therefore, BTK may also be a good target in myeloid leukemias.  
 
B-cell adaptor for phosphoinositide 3-kinase (BCAP) 
 One of the known downstream direct targets of BTK in B cells is B cell adaptor for 
phosphoinositide 3-kinase (BCAP), encoded by the Pik3ap1 gene. BCAP was discovered 
in 2000 as a novel protein that connects the B cell receptor to PI3K activation. Okada et 
al. first isolated BCAP using the immobilized N-terminal SH2 domain in chicken DT40 B 
cells, then cloned the murine counterpart from a spleen cDNA library (Okada, Maeda 
2000). The chicken BCAP contains four YxxM motifs, which is the motif that binds to 
PI3K’s p85α subunit, and the mouse BCAP protein contains three YxxM motifs (YESM, 
YESM, and YVEM). In the mouse, BCAP is highly expressed in the spleen, but small 
amounts of BCAP are also present in the thymus, lung, and liver. As for cell types, BCAP 
is expressed predominantly in hematopoietic cells, particularly B cells and macrophages 
(Okada, Maeda 2000), but is also expressed in dendritic cells, natural killer cells 
(MacFarlane, Yamazaki 2008), and hematopoietic stem and progenitor cells (Duggan, 
Buechler 2017). In B cells, BCAP is phosphorylated directly by BTK and SYK (spleen 
tyrosine kinase) following BCR activation. Once tyrosine phosphorylated at the YxxM 
motifs, phospho-BCAP can then bind to the two SH2 domains of the p85α regulatory 
subunit of PI3K (Fruman, Meyers 1998, Shoelson, Sivaraja 1993). This association 
between BCAP and p85α promotes the activity of PI3K in two distinct manners: 1) it 
increases the kinase activity of the catalytic p110 domain and 2) it recruits PI3K to 
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glycolipid-enriched microdomains (GEMs) at the plasma membrane, thus localizing PI3K 
to its PI(4,5)P2 substrate. Without the p85α subunit, B cells cannot develop properly in 
response to BCR stimulation because PI3K is integral to cell proliferation and survival 
(Fruman, Snapper 1999). 
 Originally four different isoforms of BCAP were isolated with molecular weights 
of 70, 72, 98, and 100 kDa, termed BCAP1, BCAP2, BCAP3, and BCAP4, respectively. All 
four isoforms are encoded by the same Pik3ap1 gene, and screening of a cDNA library 
showed that BCAP1 and BCAP2 are generated by an alternative sequence truncated at 
the N-terminal end (BCAP-S) while the full-length transcript (BCAP-L) gives rise to BCAP3 
and BCAP4 (Okada, Maeda 2000). The difference between BCAP-S and BCAP-L is likely 
due to alternative start sites of transcription, and the smaller differences within the 
isoform sizes (BCAP1 vs. BCAP2 and BCAP3 vs. BCAP4) are likely due to post-
translational modifications. Following BCR activation, two additional larger BCAP 
isoforms were visible (BCAP5 and BCAP6), so these may be less prevalently expressed 
species that only become visible after stimulation (Okada, Maeda 2000). It is unknown if 
these larger isoforms result from further post-translational modifications or from 
another alternative transcript. 
Architecturally, BCAP is made up of several well-defined motifs necessary for 
protein-protein interactions (Figure 1.5). It contains two ankyrin repeats and a coiled 
coil, similar to that found in the Drosophila version of BCAP, Dof, where these motifs 
were first reported. Just upstream in the BCAP protein is a Dof/BANK/BCAP (DBB) 
domain, named because it is a conserved sequence also found in Dof and another B cell  
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Figure 1.5: Schematic diagram of the structure of BCAP 
BCAP is encoded by a full-length transcript (BCAP-L) that gives rise to 100kDa and 98kDa 
proteins, and a truncated BCAP-S transcript that encodes the 72kDa and 70kDa species. 
The shortened transcript lacks the N-terminal Toll-IL-1 receptor (TIR) domain, which has 
been shown to interact with PI3K to downregulate the TLR inflammatory response. All 
isoforms of BCAP contain a Dof/BANK/BCAP (DBB) domain, which is necessary for 
dimerization; the double ankyrin repeat (AR) motif and the coiled coil (CC) motif, which 
are two protein folding motifs important for protein-protein interactions; and the 
proline-rich regions (P), which are also commonly involved in protein-protein 
interactions. 
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signaling molecule, B cell scaffold with ankyrin repeat (BANK). Previous work has shown 
that this DBB domain is required in Dof for FGF-dependent signaling and for both Dof 
and BCAP to form homodimers (Battersby, Csiszar 2003). While BCAP is not involved in 
FGF-dependent signaling, it was recently reported that BCAP-L exists as a homodimer 
(Halabi, Sekine 2017).  
In 2011, Troutman et. al reported that the N-terminal end of BCAP was 
homologous to the Toll-IL-1 receptor (TIR) domain and functioned to negatively regulate  
toll-like receptor (TLR) signaling by activating PI3K. The structure of the N-terminal 
domain of BCAP was recently confirmed to be a TIR domain by protein crystallization 
(Halabi, Sekine 2017). TLRs are activated as a component of the innate immune 
response to microbial infections by agonists such as lipopolysaccharide (LPS) from 
Gram-negative bacteria. However, the activation of TLR signaling also activates PI3K, 
which inhibits proinflammatory events and thus negatively regulates TLR signaling as a 
negative feedback mechanism (Hazeki, Nigorikawa 2007). Macrophages lacking BCAP 
have decreased PI3K activation and are hyperresponsive to TLR agonists (Ni, MacFarlane 
2012), which also renders them more vulnerable to ER stress-induced apoptosis (Song, 
Chew 2011). Finally, as previously mentioned, BCAP contains YxxM motifs that enable 
interaction with p85α’s SH2 domains once tyrosine-phosphorylated (Okada, Maeda 
2000). 
As stated above, BCAP is an important downstream target of BTK. Similar to BTK 
loss, the loss of BCAP results in defective B cell development and attenuates the 
humoral immune response, as demonstrated by Yamazaki et. al in BCAP-/- mice 
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(Yamazaki, Takeda 2002). However, although macrophages also have high BCAP 
expression, BCAP-/- mice demonstrate no defects in macrophage development 
compared to their wild-type littermates (Yamazaki, Takeda 2002). There is evidence that 
the signaling pathways involving BCAP also differ between cell types. For example, in 
mouse B cells, SYK initiates and BTK sustains the phosphorylation of BCAP; however, SYK 
does not function in a parallel fashion in myeloid cells. In fact, Ni et al. demonstrated 
that bone marrow-derived macrophages lacking SYK have increased phosphorylation of 
BCAP-L, suggesting that SYK functions to decrease BCAP phosphorylation in myeloid 
cells (Ni, MacFarlane 2012). 
Due to the incongruous functions of BCAP in various cell types, it is unknown if 
BCAP acts as a connector from BTK to PI3K signaling in myeloid cells as it does in B cells. 
Some evidence suggests that BCAP has this ability, as bone marrow-derived 
macrophages lacking both Btk and Tec expression demonstrated decreased BCAP 
phosphorylation (Tampella, Kerns 2015). Because of the role that PI3K plays in cell 
survival, proliferation, and malignancies, the potential role of BCAP as a possible 
molecule-of-interest in cancer is worth exploring. The importance of BCAP in Akt 
activation after BCR cross-linking is well-established (Castello, Gaya 2013, Qin and Chock 
2003), but its role in malignancies is largely unknown. As stated earlier, BCAP has a small 
amount of expression in the lung, and a recent study found that BCAP expression was 
increased in tumor tissues of lung cancer patients. These studies also identified miR-486 
as a direct inhibitor of BCAP, which led to inhibition of Akt and induction of autophagy 
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(Xu, Wang 2017). These findings suggest a possible clinical application of BCAP inhibition 
in cancer, including in myeloid malignancies. 
 
DNA Methyltransferase 3A (DNMT3A) 
 The addition of a methyl group to cytosine in DNA, called DNA methylation, is an 
epigenetic modification that affects embryonic development, genomic imprinting, stem 
cell behavior, and malignancies (Yang, Rau 2015). DNA methyltransferase 3A (DNMT3A) 
is an enzyme that catalyzes cytosine methylation at CpG dinucleotide sites. Typically, 
methylation in a promoter region is associated with silencing of gene expression (You 
and Jones 2012). Aberrant DNA methylation has long been observed in cancer (Baylin 
and Herman 2000) and DNMT3A has recently been identified as a commonly mutated 
gene in hematologic malignancies. 
 The mechanism of DNMT3A activity, such as how it is regulated, recruited to 
chromatin, and targeted to specific sites, is still poorly understood. Experiments using 
mouse models have provided new insight into the function of DNMT3A. Complete and 
ubiquitous loss of Dnmt3a expression in mice results in failure to thrive and death one 
month after birth (Okano, Bell 1999), reflecting the important role of DNA methylation 
during development. Mice with conditional deletion of Dnmt3a in hematopoietic stem 
cells (HSCs) have normal development, but their HSCs aberrantly favor self-renewal over 
differentiation, leading to accumulation of Dnmt3a-null HSCs in the bone marrow 
(Challen, Sun 2011). Genome-wide methylation studies have been performed to study 
the mechanism of how DNMT3A loss leads to increased self-renewal. These studies 
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found that HSCs lacking Dnmt3a expression have an overall hypomethylated profile, but 
especially affected areas of the genome are the edges of large canyon regions, which 
are enriched for genes related to self-renewal and cancer (Jeong, Sun 2014). 
Although abnormal methylation patterns have long been recognized to be 
associated with cancer, mutations in DNMT3A were only identified in 2010, specifically 
in acute myeloid leukemia (AML) patients. DNMT3A is now known to be mutated in over 
20% of AML patients (Ley, Ding 2010), in 8% of myelodysplastic syndrome (MDS) 
patients (Walter, Ding 2011), and in smaller frequencies in other leukemias. Multiple 
different mutations throughout DNMT3A have been observed, but the R882 codon in 
particular is a mutational hotspot, making up 60% of DNMT3A mutations found in AML 
patients. R882 mutations are dominant-negative, resulting in less than 80% of DNMT3A 
enzymatic activity (Kim, Zhao 2013). 
One of the critical steps in the development of malignancy is the clonal 
expansion of HSCs bearing somatic mutations. Multiple studies have found DNMT3A to 
be one of the recurrently mutated epigenetic regulators found in clonal hematopoiesis 
of normal individuals with no signs of hematologic malignancy, a phenomenon called 
clonal hematopoiesis of indeterminate potential (CHIP) (Xie, Lu 2014).  In this 
preleukemic state, almost all DNMT3A mutations are nonsynonymous, truncating, or 
splicing, and mutations in R882 are rare (Young, Challen 2016). These healthy individuals 
are at an increased risk of developing hematologic malignancy and will have a poorer 
overall prognosis (Genovese, Jaiswal 2015, Jaiswal, Fontanillas 2014). It is not surprising 
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that DNMT3A is among the first genes to acquire a preleukemic lesion since HSCs with 
mutated DNMT3A have enhanced self-renewal and expand over time. 
 DNMT3A mutations have also been identified in JMML patients as secondary 
mutations, most commonly in conjunction with PTPN11 mutations, which is important 
given the increasing recognition that secondary mutations lead to much poorer 
prognosis in JMML patients (Stieglitz, Taylor-Weiner 2015). Furthermore, the DNA 
methylation profile of JMML patients has recently been found to be predictive of 
disease outcome. Using unsupervised hierarchical clustering, Stieglitz et. al observed 
that JMML patients could be clustered into low, intermediate, and high genome-wide 
methylation. Those in the low methylation cluster had the highest survival rate, with 
almost all patients experiencing spontaneous resolution of disease (Stieglitz, Mazor 
2017). Consistent with these findings, there is a case report describing a JMML patient 
treated with azacitidine, a DNA methyltransferase inhibitor, who had impressive 
resolution of hepatosplenomegaly and monocytosis even prior to allogeneic HSCT 
(Furlan, Batz 2009). Based on the prediction that patients exhibiting hypermethylated 
profiles would respond to DNA hypomethylating agents, there is an ongoing phase I/II 
clinical trial testing the effect of azacitidine in JMML patients (NCT02447666). Although 
mutations in DNMT3A lead to decreased methyltransferase activity and thus focal areas 
of CpG hypomethylation, the presence of secondary mutations in patients are 
associated with an overall hypermethylated state (Stieglitz, Mazor 2017). These findings 
suggest that DNMT3A activity significantly affects disease progression and overall 
prognosis in JMML. 
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Summary and Significance 
JMML is a childhood disease that, albeit rare, is extremely aggressive and 
currently lacks effective therapies and thus has a pressing need for more investigation. 
The only curative treatment is allogeneic hematopoietic stem cell transplant (Loh 2011), 
yet even this aggressive intervention elicits a 5-year event-free survival of only 50% 
(Bergstraesser, Hasle 2006, Locatelli, Nöllke 2005). This is in stark contrast to other 
pediatric leukemias, such as acute lymphoblastic leukemia (ALL), which have made great 
strides forward in improving care with overall survival over 80% (Gaynon, Angiolillo 
2010). In recent years, JMML researchers have made efforts to better genetically define 
JMML patients, with whole genome studies performed to find secondary mutations 
(Stieglitz, Taylor-Weiner 2015). The hope is that, by understanding the underlying 
molecular mechanisms, patients can receive more personalized and targeted 
therapeutics. 
For the five causative gene mutations that make up 90% of JMML cases, the 
underlying signaling abnormality in common is hyperactivated RAS signaling. Either RAS 
itself is mutated (KRAS or NRAS) or NF1, the RAS-GAP protein responsible for 
hydrolyzing RAS-GTP into RAS-GDP, acquires a genetic lesion. CBL and the most 
commonly mutated protein, SHP2, also have upregulated RAS signaling, but the 
mechanism for these two proteins is still unknown. Targeting aberrant RAS signaling, 
which is also seen in many other malignancies, has proven difficult. The strategy of GTP-
competitive inhibitors against RAS has not been successful because of the high affinity 
RAS has for GTP (Gysin, Salt 2011). Because RAS must traffic to the plasma membrane to 
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function as a signal transducer, another protein called farnesyl-transferase normally 
adds hydrophobic farnesyl groups to the mature RAS protein. Therefore, farnesyl-
transferase inhibitors have been developed as an alternate strategy to GTP-competitive 
inhibitors for RAS inhibition. Tipifarnib is one such inhibitor whose mechanism-of-action 
is to inhibit prenylation of the tail motif of RAS. Unfortunately for JMML patients, 
tipifarnib’s initial success in vitro did not translate in clinical trials (Stieglitz, Ward 2015). 
The failure of tipifarnib is believed to be due to geranylgeranylation, another form of 
post-translational modification prenylation, that allows RAS to continue to interact with 
the membrane even lacking farnesylation (Epling-Burnette and Loughran 2010).  
Because of the difficulties in targeting RAS itself, the next best strategy is to 
target an effector in a downstream signaling pathway, such as in the MAPK pathway or 
the PI3K/Akt pathway. For the MAPK pathway, there is an ongoing phase II clinical trial 
in patients with relapsed/refractory JMML using trametinib, a MEK inhibitor 
(NCT03190915). In addition to the MAPK pathway, PI3K is known to be hyperactivated 
in a multitude of malignancies with many drugs developed for clinical use, as described 
earlier. The pan-PI3K inhibitors have proven to be too toxic for use in humans, but 
isoform-specific inhibitors are more tolerable. Our lab has previously shown that in vitro 
inhibition of the hematopoietic-specific catalytic subunit, p110δ, using GS-9820 
significantly reduced GM-CSF-stimulated phosphorylation of Akt and Erk and cell 
hyperproliferation in the context of gain-of-function (GOF) mutant Shp2. However, 
promising findings in vitro do not always translate in vivo. Furthermore, single-agent 
therapy is unlikely to be effective because of the development of resistance and the 
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upregulation of parallel signaling pathways. With this in mind, we moved forward with 
studies employing GS-9820 in vivo in GOF Shp2-bearing mice and further explored the 
p110δ signaling pathway to find other potential targets. 
In the following work, we used pharmacologic inhibitors of p110δ and BTK in 
mice conditionally expressing a GOF Shp2 mutation in cells of the myeloid lineage. We 
first treated mice with GS-9820 and showed that the strong effect on signaling in bone 
marrow-derived macrophages and the reduction in low-density mononuclear cell 
hyperproliferation that our laboratory had previously seen in vitro translated into 
reduced spleen size and prolonged survival in vivo (Chapter Three). We also found that 
drug-treated mice had reduced stem/progenitor cells in the bone marrow and increased 
mature myeloid cells in the peripheral blood, suggesting that the inhibition of p110δ 
signaling may disrupt the nurturing microenvironment for progenitors and induce 
myeloid differentiation (Chapter Three).  
In our search for molecules potentially cooperating with p110δ signaling, we 
focused our efforts on BTK, as BTK has recently emerged as a highly successful target of 
inhibition in B cell malignancies. First, we demonstrated that BTK and the known 
downstream target, PLCγ2, are both hyperphosphorylated in GOF Shp2 myeloid cells 
(Chapter Four). We next used BTK and p110δ inhibitors to demonstrate that PI3K is 
upstream of BTK and that BTK cooperates with p110δ to cause hyperactivation of Akt 
and Erk in mutant Shp2-expressing macrophages (Chapter Four). We further found that 
the two inhibitors cooperate to reduce GM-CSF-stimulated hyperproliferation of mutant 
Shp2-expressing bone marrow low-density mononuclear cells. We next treated mice in 
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vivo with the drugs as single-agents or as a combination therapy and observed 
significantly decreased splenomegaly and peripheral blood WBC counts in the dual 
inhibitor-treated group (Chapter Four). Here again, we noticed decreased 
stem/progenitor cells in the bone marrow compartment with an increase in terminally 
differentiated myeloid cells in the peripheral blood compartment. Despite these 
significant results, however, we did not observe any change in phospho-PLCγ2 in the 
presence of the BTK inhibitor (Chapter Four). This finding is inconsistent with the 
function of PLCγ2 in B cell receptor signaling, where it is the downstream target of BTK 
that leads to the activation of Erk (Hashimoto, Okada 1998, Kim, Sekiya 2004). 
In order to obtain a better understanding of the mechanism of signaling from 
BTK to Akt and Erk in myeloid cells, we performed a literature search for other targets of 
BTK that could potentially lead to activation of these downstream effectors. We found 
that BCAP had recently been identified as a protein with reduced phosphorylation in 
bone marrow-derived macrophages lacking Btk and Tec expression (Tampella, Kerns 
2015) and that it had long been known to connect BTK to PI3K in B cells (Okada, Maeda 
2000). As PI3K certainly positively signals to activate Akt and Erk, we hypothesized that 
BCAP connects BTK to the upregulation of PI3K activity in GOF Shp2-expressing myeloid 
cells. When we tested this hypothesis, we found that BCAP is phosphorylated in mutant 
Shp2 macrophages specifically in the two larger isoforms that are needed for PI3K 
activation (Chapter Five). We further demonstrated that BTK inhibition leads to a dose-
dependent reduction in this phosphorylation (Chapter Five), suggesting that BTK is 
signaling upstream of BCAP in myeloid cells as well as B cells. Since one of the ways that 
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BCAP increases PI3K catalytic activity is by binding to the regulatory p85α domain, we 
explored the mechanism of this interaction using p85α constructs with mutated SH2 
domains. We found reduced interaction between BCAP and p85α after mutating the 
two SH2 domains, indicating that one or both of these domains are necessary for BCAP 
binding (Chapter Five). 
Finally, we explored the consequences of concurrent expression of the Shp2D61Y 
mutation and Dnmt3a haploinsufficiency. We observed that mice bearing both 
mutations had accelerated development of leukemia and earlier mortality (Chapter Six). 
The double mutant mice had increased myeloid cells in the periphery and granulocyte 
macrophage progenitors in the bone marrow. We also saw evidence for a novel 
phenotype of defective erythrocyte maturation leading to anemia in the double mutant 
mice, with compensatory erythropoiesis in the spleen (Chapter Six). 
From our results, we propose that the myeloproliferative neoplasm caused by 
GOF Shp2 mutations is facilitated by hyperactivated PI3K, particularly the catalytic 
subunit p110δ, and significant improvements can be made by treatment with a p110δ 
inhibitor in vivo. Our findings also suggest that in mutant Shp2-expressing myeloid cells, 
BTK promotes p110δ activity by forming a positive feedback loop with PI3K and BCAP, 
thus leading to augmented hyperphosphorylation of Akt and Erk and enhanced 
hyperproliferation in response to GM-CSF. The dual inhibition of p110δ and BTK 
represents a novel effective treatment strategy for JMML and other myeloid diseases 
induced by oncogenic Shp2. In addition to targeting GM-CSF-stimulated signaling 
proteins p110δ and BTK, our findings also provide a functional mechanism underlying 
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the observed inferior prognosis for JMML patients bearing mutations in both PTPN11 
and DNMT3A and support the use of hypomethylating agents in JMML. 
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CHAPTER TWO 
MATERIALS AND METHODS 
Materials 
Plasmids 
pMIEG3 
WT Shp2 and Shp2 E76K constructs in tandem with enhanced green fluorescent protein 
(eGFP) were expressed in pMIEG3 plasmid. These constructs were previously made in 
our laboratory (Chan, Leedy 2005). 
pQCXIN 
WT Shp2 and Shp2 E76K constructs were expressed in the pQCXIN plasmid. This plasmid 
has the neomycin resistance cassette with an IRES sequence. cDNA from murine WT 
Shp2 and mutated Shp2 E76K were obtained from previously made constructs in pCMV2 
plasmid from our laboratory. 
pMSCV 
WT p85α, p85α R358A, p85α R649A, and p85α R358A/R649A constructs were expressed 
using pMSCV plasmid. cDNA from murine p85α and the mutated forms of p85α were 
previously generated by site-directed mutagenesis and fused in-frame to the DNA 
sequence for yellow fluorescent protein (YFP) as a marker.  
pCMV6 
BCAP construct was expressed using pCMV6 plasmid. cDNA from murine BCAP 
(purchased from Origene) was fused in-frame to the DNA sequence for mCherry as a 
marker.   
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Primers 
Standard polymerase chain reactions (PCRs) were performed using oligonucleotides 
synthesized by Invitrogen. The primers used for genotyping are listed in Table 2.1. 
Table 2.1: Genotyping primers 
Gene Forward (5’ – 3’) Reverse (3’ – 5’) 
Shp2 Exon 3 
(Shp2D61Y) 
5’-CAAGGTGAGTGGGCGTTTCAT 
TTTAAC-3’ 
5’-ACCTTTCAGAGGTAGGGTCTGCA 
C-3’ 
Mx1-cre 5’-GCCTGCATTACCGGTCGATGC 
AACGAGTG-3’ 
5’-CTGGCAATTTCGGCTATACGTAA 
CAGGGTG-3’ 
Neo cassette 
(Shp2E76K) 
5’-TGGGAAGACAATAGCAGGCA 
-3’ 
5’-CCCACTCACCTTGTCATGTA-3’ 
LysM-cre 5’-CCCAGAAATGCCAGATTACG-
3’ 
5’-CTTGGGCTGCCAGGATTTCTC-3’ 
Dnmt3a loxP 5’-CTGTGGCATCTCAGGGTGATG 
AGCA-3’ 
5’-AAGCCTCAGGCCCTCTAGGCAAG 
A-3’ 
 
Mice 
LSL-Shp2D61Y/+ 
LoxP-STOP-LoxP (LSL)-Shp2D61Y/+ mice were a gift from Dr. Benjamin G. Neel. The Ptpn11 
gene has insertion of an LSL cassette in order the express the allele containing the 
knock-in D61Y mutation only after cre-mediated recombination. These mice were 
crossed with Mx1-cre mice (Chan, Kalaitzidis 2009). 
Mx1-cre 
Mx1-cre transgenic mice were a gift from Dr. Reuben Kapur (Kuhn, Schwenk 1995). The 
Mx1 promoter is induced by three intraperitoneal injections of 300ug polyI:polyC to 
stimulate the γ-interferon response. 
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LSL-Shp2E76K/+ 
LSL-Shp2E76K/+ mice were a gift from Dr. Cheng-Kui Qu. The Ptpn11 gene has insertion of 
an LSL cassette in order the express the allele containing the knock-in E76K mutation 
only after cre-mediated recombination. These mice were crossed with LysM-cre mice 
(Xu, Liu 2011). 
LysM-cre 
LysM-cre mice were purchased from The Jackson Laboratory (Clausen, Burkhardt 1999). 
Cre recombinase is inserted into the first coding ATG of the lysozyme 2 gene (Lyz2) and 
therefore is expressed under the control of the Lyz2 promoter. This results in targeted 
expression in the myeloid cell lineage, particularly in mature macrophages and 
granulocytes. 
Dnmt3aflox/flox 
Mice with a conditional knockout Dnmt3a allele were a gift from Dr. Reuben Kapur (Yu, 
Zhou 2012). 
 
Antibodies 
Immunoprecipitation and immunoblot 
Table 2.2: Primary antibodies for immunoblot 
Primary antibody Vendor Clone 
Total Akt Cell Signaling N/A 
Phospho-Akt (S473) Cell Signaling 587F11 
Phospho-Akt (S473) Cell Signaling D9E 
Total Erk Cell Signaling N/A 
Phospho-Erk (T202/T204) Cell Signaling N/A 
Total BTK Cell Signaling C82B8 
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Table 2.2: Primary antibodies for immunoblot (continued) 
Primary antibody Vendor Clone 
Phospho-BTK (Y223) Cell Signaling N/A 
Total PLCγ2 Cell Signaling N/A 
Phospho-PLCγ2 (Y759) Cell Signaling N/A 
Phospho-PLCγ2 (Y1217) Cell Signaling N/A 
p85α Cell Signaling 6G10 
BCAP R&D Systems 501813 
BCAP R&D Systems N/A 
Phospho-tyrosine Millipore 4G10 
GAPDH Biodesign International 6C5 
 
Table 2.3: HRP Secondary antibodies 
Secondary antibody Vendor 
Goat Anti-Rabbit IgG HRP Santa Cruz 
Goat Anti-Mouse IgG HRP Santa Cruz 
Goat Anti-Rabbit IgG HRP Cell Signaling 
Horse Anti-Mouse IgG HRP Cell Signaling 
Donkey Anti-Goat IgG HRP R&D Systems 
 
Table 2.4: Immunoprecipitation antibodies 
Antibody Vendor Concentration 
BCAP R&D Systems 5μg/μL 
p85α Cell Signaling 1:25 
 
Flow cytometry 
Table 2.5: Primary antibodies for flow cytometry 
Primary antibody Fluorophore Vendor 
Sca1 PE BD Biosciences 
cKit APC BD Biosciences 
Gr1 FITC eBioscience 
Mac1 APC BD Biosciences 
B220 PE BD Biosciences 
CD4 N/A – biotinylated BD Biosciences 
CD8 N/A – biotinylated BD Biosciences 
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Table 2.5: Primary antibodies for flow cytometry (continued) 
Primary antibody Fluorophore Vendor 
Mac1 N/A – biotinylated BD Biosciences 
Gr1 N/A – biotinylated BD Biosciences 
CD4 N/A – biotinylated BD Biosciences 
CD8 N/A – biotinylated BD Biosciences 
B220 N/A – biotinylated BD Biosciences 
Ter119 N/A – biotinylated BD Biosciences 
IL7Rα N/A – biotinylated BD Biosciences 
CD19 N/A – biotinylated BD Biosciences 
CD3 N/A – biotinylated BD Biosciences 
CD71 FITC BD Biosciences 
CD36 APC BD Biosciences 
 
Table 2.6: Secondary antibodies 
Streptavidin fluorophore Vendor 
Streptavidin-PerCPcy5.5 eBioscience 
Streptavidin-APC eBioscience 
 
Inhibitors 
Table 2.7: Inhibitors 
Inhibitor Vendor/Source Target 
GS-9820 Gift from Gilead Sciences p110δ 
ACP-196 Gift from Acerta Pharma BTK 
ACP-319 Gift from Acerta Pharma p110δ 
 
Kits 
Table 2.8: Kits 
Kit Vendor Catalog Number 
SuperSignal West Dura Extended Duration 
Substrate 
Thermo Scientific 34076 
Profection Mammalian Transfection Promega E1200 
Plasmid Maxi-Prep Kit Invitrogen K210007 
Mini-prep kit Qiagen 27106 
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Methods 
Cell Culture 
Primary Murine Bone Marrow-Derived Low-Density Mononuclear Cells (LDMNCs) 
Primary murine bone marrow-derived LDMNCs were isolated from total bone marrow 
cells by Histopaque ficoll gradient (Sigma-Aldrich) and cultured in IMDM (Invitrogen), 
20% FBS (Hyclone), 2% penicillin/streptomycin (Invitrogen), granulocyte-colony-
stimulating factor (G-CSF), stem cell factor (SCF), and thrombopoietin (TPO) at 
100ng/mL concentration each. LDMNCs were maintained at 37°C and 5% CO2 for a 
maximum of 5 days. 
Adherent Macrophage Progenitor Cells 
Primary murine LDMNCs were cultured in IMDM, 20% FBS, 2% penicillin/streptomycin, 
and 25ng/mL macrophage-colony-stimulating factor (M-CSF) for 7-10 days at 37°C and 
5% CO2 to generate adherent macrophage progenitors. The media was changed after 
cells became adherent at day 5 and every 2 days thereafter. 
Eco-Phoenix Packaging Cells 
Eco-Phoenix packaging cell were cultured in DMEM (Invitrogen), 10% FBS, 1% 
Penicillin/Streptomycin, 1% L-glutamine (Invitrogen), and 1% sodium pyruvate 
(Invitrogen) at 37°C and 5% CO2. Cells were split every 2-3 days. 
NIH3T3 cells 
Native NIH3T3 cells were cultured in DMEM, 10% FBS, 1% penicillin/streptomycin, 1% L-
glutamine, and 1% sodium pyruvate at 37°C and 5% CO2. Cells were split every 2-3 days. 
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Following transduction with the pQCXIN-Shp2 plasmid containing neomycin resistance, 
cells were cultured in media containing 600μg/mL of neomycin (G418) for selection. 
 
Retroviral Supernatant Production 
Retroviral supernatant were produced by transfecting the Eco-Phoenix cells with 
retroviral vector plasmids using calcium phosphate transfection (ProFection® 
Mammalian Transfection System, Promega). Supernatants, collected at 48 and 72 hours 
post-transfection were filtered through 0.45μm filters. 
 
Retroviral Transduction of NIH3T3 cells 
NIH3T3 cells were transduced with 1mL of pQCXIN-Shp2, pQCXIN-Shp2E76K, pMSCV-
p85α, pMSCV-p85α R358A, pMSCV-p85α R649A, pMSCV-p85α R358A/R649A, or 
pCMV6-Bcap retroviral supernatant in one well of a 6-well non-tissue culture plate, with 
8ug of polybrene (Sigma). Plates were incubated for 24 hours at 37°C, then viral 
supernatant was replaced with DMEM, 10% FBS, 1% penicillin/streptomycin, 1% L-
glutamine, and 1% sodium pyruvate, and plates were incubated for another 24 hours. At 
72 hours after the start of transduction, cells were started on selection media 
(neomycin) or collected for fluorescence-activated cell sorting (FACS). 
 
Cell Sorting 
Retrovirally transduced cells were sorted using FACS to collect yellow fluorescent 
protein- and mCherry-positive (YFP+mCherry+) cells. 
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Generation of NIH3T3 cells expressing constructs of Shp2, p85α, and BCAP 
Native NIH3T3 cells were first transduced with either WT Shp2 or Shp2E76K plasmid and 
cultured in neomycin-containing selection media. NIH3T3 cells stably expressing Shp2-
neoR were used as recipients for p85α transduction, and sorted on YFP+ cells. NIH3T3 
cells stably expressing both Shp2-neoR and p85α-YFP were used as recipients for 
transduction with BCAP-mCherry, and sorted on mCherry+ cells. This resulted in four 
NIH3T3 cell lines: 1) WT Shp2, WT p85α, BCAP; 2) WT Shp2, R358A/R649A p85α, BCAP; 
3) Shp2E76K, WT p85α, BCAP; and 4) Shp2E76K, R358A/R649A p85α, BCAP (Figure 5.5). 
 
Isolation of Total Cellular Protein Lysates 
Cells were washed twice in cold PBS and incubated on ice for 5-10 minutes in a lysis 
buffer containing 50mM Hepes, 150mM NaCl, 10% Glycerol, 1% Triton X, 1.5mM MgCl2, 
1mM EGTA, 100mM NaF, and 10mM NaPPi with Na3VO4, ZnCl2, PMSF, and protease 
inhibitor cocktail (Sigma). Protein lysates were collected by scraping, then centrifuged at 
13,200 rpm for 15 minutes at 4°C and quantified using Bradford reagent. 
 
Immunoblot Analysis 
Protein lysates were separated by SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
and transferred to nitrocellulose membrane, which was then incubated with shaking 
overnight in primary antibody (see Table 2.2) at 4°C. The membrane was then washed 
and incubated with HRP-conjugated secondary antibody (see Table 2.3), developed with 
SuperSignal (see Table 2.8), and exposed by using a Bio-Rad Imager. 
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Immunoprecipitation 
Equal amounts of fresh protein lysates per sample were aliquoted into 1.5mL Eppendorf 
tubes, volumes were equalized with lysis buffer, HNTG buffer (1% Triton X, 50mM 
Hepes, 50mM NaCl, 5mM EDTA, 0.1% BSA, 50mM NaF with Na3VO4, ZnCl2, PMSF, and 
protease inhibitor cocktail) was added to bring total volume to 500μL, and anti-BCAP or 
anti-p85α antibody was added (see Table 2.4). Tubes were rotated at 4°C for 2 hours, 
then 25μL of HNTG-washed Protein A/G PLUS-Agarose beads (Santa Cruz) were added 
per tube. Tubes were rotated at 4°C overnight, then washed three times with wash 
buffer (1% Triton X, 50mM Hepes, 120mM NaCl, 5mM EDTA, 50mM NaF with Na3VO4, 
ZnCl2, PMSF, and protease inhibitor cocktail) for 15 minutes at 4°C rotating, spinning 
down at 3000rpm for 30 seconds in between washes, and used for immunoblot analysis. 
 
[3H]-Thymidine Incorporation Assay 
Cells were starved for 4-5 hours in IMDM containing 0.2% Bovine Serum Albumin (BSA) 
(Roche) and then plated in 96-well plates (200μL IMDM with 2% penicillin/streptomycin 
per well) for [3H]-thymidine incorporation assays (2 x 104 cells/well) either at baseline 
(no growth factor) or in the presence of 10ng/mL granulocyte macrophage-colony-
stimulating factor (GM-CSF), with or without indicated inhibitors, and incubated 
overnight at 37°C. The following morning, cells were pulsed with 1μCi of [3H]-thymidine 
and incubated for 5-6 hours at 37°C. [3H]-thymidine incorporation was measured using 
an automated 96-well cell harvester and scintillation counter (Brandel, Gaithersburg, 
MD). 
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Methylcellulose Colony-Forming Assay 
Bone marrow low-density mononuclear cells (1.0 x 105) were plated in triplicate in 1mL 
progenitor assays containing 1% methylcellulose (ES-Cult® M3120, Stem Cell 
Technologies), 30% FBS, 2% penicillin/streptomycin, 1% glutamine, and 80μM β-
mercaptoethanol in the presence of increasing concentrations of GM-CSF (0, 0.01, 0.1, 
or 10ng/mL). Methylcellulose plates were incubated at 37°C for 7 days before total 
number of colonies were counted. 
 
In vivo drug treatment of mice 
A solution of 0.5% w/v methylcellulose (Sigma) and 0.1% v/v Tween-80 (Sigma) was 
made in water. Using this solution, a stock of drug inhibitor (GS-9820, ACP-196, or ACP-
319; see Table 2.7) was made, aliquoted into 1mL aliquots, and stored at 4°C during the 
21 days of treatment. Prior to each dosing, the necessary amount of drug and vehicle 
were brought to room temperature and mixed thoroughly. Mice were dosed BID (twice 
a day) via oral gavage. 
 
Flow Cytometry Analysis 
Cell suspensions were incubated for 5 minutes with 10% rat serum (MP Biomedicals) 
and 0.2% BSA (Roche) in PBS, stained for 30 minutes at 4°C with primary antibody (see 
Table 2.5), washed with PBS, then stained for 15 minutes at 4°C with secondary 
antibody (see Table 2.6). The analyzer used for flow cytometry was a BD LSR II or a BD 
FACSCanto II and data was analyzed using CellQuest. 
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Complete Blood Counts 
Peripheral blood was collected from the saphenous vein of mice and complete blood 
counts were measured using a Hemavet 950 (Drew Scientific Group) or an Element HT5 
Hematology Analyzer (Heska). 
 
Statistical Analysis 
Statistics for Figures 3.8 and 4.5 were done using log-rank (Mantel-Cox) test. Statistics 
for all other experiments were performed using unpaired, two-tailed Student’s t test. 
Figures show mean +/- standard deviation (S.D.) or mean +/- standard error of the mean 
(S.E.M.) as indicated in the figure. 
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CHAPTER THREE 
PHARMACOLOGIC INHIBITION OF PI3K p110δ REDUCES SPLENOMEGALY AND 
PROLONGS SURVIVAL IN MUTANT Shp2E76K-EXPRESSING MICE 
Introduction 
When studying gain-of-function (GOF) mutations in Shp2, which is the most 
common mutation found in juvenile myelomonocytic leukemia (JMML) patients, our 
laboratory has focused on the downstream target phosphoinositide 3-kinase (PI3K). We 
previously found that genetic and pharmacologic inhibition of the hematopoietic-
specific catalytic subunit of PI3K, p110δ, is uniquely important in promoting GOF Shp2-
induced leukemia (Goodwin, Li 2014). A mouse model of JMML with a GOF Shp2 
mutation (Shp2D61Y/+;Mx1-cre+) was crossed with mice bearing a mutated p110δ with 
complete loss of catalytic activity. These Shp2D61Y/+;Pik3cdD910A/D910A;Mx1-cre+ mice had 
reduced splenomegaly, decreased phosphorylation of Akt and Erk, and decreased 
progenitor cell hypersensitivity to GM-CSF compared to the Shp2D61Y/+;Mx1-cre+ mice. A 
similar mouse model with the same GOF Shp2, but with complete loss of p110α 
expression (Shp2D61Y/+;Pik3caflox/flox;Mx1-cre+), had no differences in comparison to the 
Shp2D61Y/+;Mx1-cre+ mice. These findings demonstrated that the hematopoietic-specific 
p110δ subunit, and not the ubiquitously expressed p110α subunit, is essential for GOF 
Shp2-induced myeloproliferative neoplasm. Furthermore, pharmacologic inhibition of 
p110δ in vitro using the Gilead Sciences small molecule GS-9820, or the FDA-approved 
inhibitor idelalisib, decreased phospho-Akt and –Erk, proliferation of Shp2D61Y/+ cells, 
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and GM-CSF hypersensitivity of primary mononuclear cells from JMML patients 
(Goodwin, Li 2014). 
The PI3K p110δ-specific inhibitor idelalisib was FDA-approved in 2014 for the 
treatment of patients with relapsed chronic lymphocytic leukemia and follicular 
lymphoma (Miller, Przepiorka 2015). However, the effectiveness of p110δ inhibition in 
JMML, a disease that lacks effective chemotherapies, has not yet been studied. 
Therefore, following our laboratory’s promising results demonstrating reduced GM-CSF 
hypersensitivity and proliferation of GOF Shp2-expressing murine cells and primary 
JMML cells in vitro, we assessed the effect of p110δ inhibition on GOF Shp2-expressing 
mice in vivo as the next step in exploring p110δ inhibition as a potential treatment 
strategy for JMML. We utilized the p110δ inhibitor GS-9820 (hereafter PI3Kδ inhibitor), 
which has superior pharmacokinetics in murine models compared to idelalisib (Dr. 
Stacey Tannheimer, personal communication) (Carter, Cox 2017). 
 
Results 
Pharmacologic inhibition of PI3Kδ using the specific and potent inhibitor, GS-9820, 
significantly reduces gain-of-function mutant Shp2-induced splenomegaly  
Having seen the effectiveness of p110δ inhibition in vitro for correcting GOF 
Shp2-induced leukemia characteristics, we next wished to test the usefulness of 
treatment with a p110δ inhibitor in vivo. To do this, we used mice expressing the Shp2 
mutation E76K, which is the most frequent and the most active SHP2 mutation in JMML 
patients. The E76K mutant allele is conditionally expressed by Cre recombinase under 
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the control of the promoter of the lysozyme 2 gene. The LysMcre+ mice express Cre only 
in cells of the myeloid lineage, including monocytes, mature macrophages, and 
granulocytes (Clausen, Burkhardt 1999). Shp2E76K/+;LysMcre+ mice have been previously 
reported to reliably develop a myeloid expansion and myeloproliferative neoplasm that 
closely mimics human JMML. These animals begin to die at 28 weeks of age and have a 
median survival of 36 weeks (Xu, Liu 2011). Thus, we determined 12-20 weeks of age to 
be an ideal treatment window, as this period provides sufficient time for the 
development of disease but typically precedes MPN-induced mortality. We treated 
Shp2E76K/+;LysMcre+ mice between 12 and 20 weeks of age with 30mg/kg of PI3Kδ 
inhibitor (GS-9820) or vehicle (0.5% w/v methylcellulose + 0.1% v/v Tween 80) BID via 
oral gavage for 21 days. In our first of two cohorts, we had seven mice per treatment 
group and euthanized all fourteen mice 16 hours following the final dose of PI3Kδ 
inhibitor or vehicle. 
When euthanized directly after completing 21 days of treatment, the PI3Kδ 
inhibitor-treated mice had significantly reduced spleen-to-body weight ratio in 
comparison to the vehicle-treated mice (Figure 3.1). To test the hypersensitivity of 
hematopoietic progenitors to GM-CSF, a hallmark feature of JMML, we measured the 
colony-forming ability of bone marrow low-density mononuclear cells (LDMNCs) in 
response to increasing concentrations of GM-CSF. 100,000 LDMNCs from each mouse 
were plated in semi-solid methylcellulose media containing 0, 0.01, 0.1, or 10ng/mL 
GM-CSF and colonies were counted 7 days later. LDMNCs isolated from PI3Kδ inhibitor-  
 
51 
 
 
Figure 3.1: PI3Kδ inhibition in vivo decreases splenomegaly in Shp2E76K/+;LysMcre+ mice 
The spleen to body weight ratio of mice at the end of 21 days of treatment. Mice 
between the ages of 12-20 weeks were treated via oral gavage BID with either vehicle or 
30mg/kg of PI3Kδ inhibitor. n=7 per group, *p=0.03 comparing the PI3Kδ inhibitor-
treated mice to vehicle-treated mice, statistical analyses performed by unpaired, two-
tailed, Student’s t-test. 
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Figure 3.2: Time-limited PI3Kδ inhibition in vivo does not permanently correct GM-CSF 
hypersensitivity of bone marrow progenitors in Shp2E76K/+;LysMcre+ mice 
Number of colonies formed in methylcellulose colony forming assays, shown as a 
percentage of total colonies at maximum GM-CSF concentration. Bone marrow LDMNCs 
were collected from 7 PI3Kδ inhibitor-treated mice and 7 vehicle-treated mice and 
plated in triplicate per each concentration of GM-CSF. Colonies were counted 7 days 
after plating. 
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treated mice demonstrated similar GM-CSF hypersensitivity compared to the vehicle-
treated mice, indicating that pharmacologic inhibition of PI3K p110δ does not 
permanently correct GM-CSF hypersensitivity of GOF Shp2-expressing cells (Figure 3.2). 
 
Pharmacologic inhibition of PI3Kδ reduces bone marrow hematopoietic stem/progenitor 
cells and increases mature myeloid cells in the periphery of gain-of-function Shp2-
expressing mice 
To investigate how PI3Kδ inhibitor treatment induced the functional effect of 
reduced spleen size, we phenotypically analyzed the bone marrow, spleen, and 
peripheral blood for hematopoietic stem/progenitor cells (lineage-Sca1+cKit+, LSK) and 
for terminally differentiated hematopoietic cells. The frequency of LSK cells was 
significantly reduced in the bone marrow of PI3Kδ inhibitor-treated mice and trended 
lower in the spleen and peripheral blood (Figure 3.3). When examining hematopoietic 
differentiation, we found no significant difference in myeloid progenitor populations 
(CMPs, GMPs, or MEPS, data not shown) or in the frequency of terminally differentiated 
CD4+, CD8+ (T cells), B220+ (B cells), and Gr1+Mac1+ (myeloid cells) in the bone marrow 
(Figure 3.4) and spleen compartments (Figure 3.5). However, the frequency of 
peripheral blood Gr1+Mac1+ cells was significantly increased in the PI3Kδ inhibitor-
treated mice compared to vehicle-treated mice (Figure 3.6). Furthermore, the Mac1+ 
mean fluorescence intensity (MFI) in the peripheral blood was significantly higher in 
PI3Kδ inhibitor-treated mice (Figures 3.7). Collectively, these findings suggest that PI3K  
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Figure 3.3: PI3Kδ inhibition in vivo decreases Lin-Sca1+Kit+ progenitor cells in the bone 
marrow of Shp2E76K/+;LysMcre+ mice 
Average percentage of Lin-Sca1+Kit+ (LSK) cells in bone marrow (BM), spleen (SP), and 
peripheral blood (PB), n=7 per group, *p=0.026 comparing LSK cells in the bone marrow 
of PI3K inhibitor-treated mice to vehicle-treated mice, statistical analyses performed 
by unpaired, two-tailed, Student’s t-test. 
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Figure 3.4: PI3Kδ inhibition in vivo does not affect terminally differentiated 
hematopoietic cell populations in the bone marrow of Shp2E76K/+;LysMcre+ mice 
Average percentage of bone marrow T cells (CD4+CD8+), B cells (B220+), and myeloid 
cells (Gr1+Mac1+) gated on live events, n=7 per treatment group. 
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Figure 3.5: PI3Kδ inhibition in vivo does not affect terminally differentiated 
hematopoietic cell populations in the spleen of Shp2E76K/+;LysMcre+ mice 
Average percentage of spleen T cells (CD4+CD8+), B cells (B220+), and myeloid cells 
(Gr1+Mac1+) gated on live events, n=7 per treatment group. 
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Figure 3.6: PI3Kδ inhibition in vivo increases the terminally differentiated myeloid cells 
in the peripheral blood of Shp2E76K/+;LysMcre+ mice 
Average percentage of peripheral blood T cells (CD4+CD8+), B cells (B220+), and myeloid 
cells (Gr1+Mac1+) gated on live events, n=7 per treatment group, *p=0.05 comparing the 
percentage of myeloid cells in the peripheral blood of PI3K inhibitor-treated mice to 
vehicle-treated mice, statistical analyses performed by unpaired, two-tailed, Student’s t-
test. 
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Figure 3.7: PI3Kδ inhibition in vivo increases the mean fluorescent intensity of Mac1 in 
the peripheral blood of Shp2E76K/+;LysMcre+ mice 
(A) Representative flow cytometry diagrams showing Mac1 brightness in the peripheral 
blood of vehicle-treated and PI3K inhibitor-treated mice. (B) Average Mac1 mean 
fluorescent intensity (MFI) in peripheral blood, n=7 per group, *p=0.0029 comparing 
PI3K inhibitor-treated to vehicle-treated mice, statistical analyses performed by 
unpaired, two-tailed, Student’s t-test. 
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p110δ inhibition induced stem/progenitor terminal differentiation and reduced the self-
renewal and hyperproliferation of immature myeloid cells. 
 
Pharmacologic inhibition of PI3Kδ significantly prolongs survival of gain-of-function 
mutant Shp2-expressing mice 
A second cohort of Shp2E76K/+;LysMcre+ mice was made up of 15 mice per 
treatment group that were treated with PI3Kδ inhibitor or vehicle as described above. 
The second cohort of mice was followed long-term for overall survival with peripheral 
blood counts assessed every 4 to 6 weeks. Each treatment group consisted of 6 male 
mice and 9 female mice, and groups were age-matched with an average age of 114 days 
for the vehicle-treated mice and 109 days for the PI3Kδ inhibitor-treated mice. Survival 
of the PI3Kδ inhibitor-treated mice was significantly prolonged compared to their 
vehicle-treated counterparts (Figure 3.8). Serial peripheral blood WBC counts were 
similar between the two groups until approximately 18 weeks following the start of 
treatment, when WBC counts in the vehicle-treated animals started increasing 
compared to the PI3Kδ inhibitor-treated mice (Figure 3.9). Notably, the period of time of 
increasing WBC counts in the vehicle-treated animals coincided with the period of time 
when the survival curves started to separate (20 – 35 weeks). Later at 37 weeks, the 
drug-treated mice also demonstrated an increase in WBC counts, which corresponded 
to this group’s cluster of deaths between 38 – 40 weeks.  
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Figure 3.8: PI3Kδ inhibitor-treated Shp2E76K/+;LysMcre+ mice have prolonged survival 
compared to vehicle-treated mice  
Kaplan-Meier survival curve of days elapsed from start of treatment until death, n=15 
per treatment group, *p=0.0092 comparing survival after treatment for PI3K inhibitor-
treated mice and vehicle-treated mice, statistical analyses performed by log-rank 
(Mantel-Cox) test. 
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Figure 3.9: Vehicle- and PI3Kδ inhibitor-treated Shp2E76K/+;LysMcre+ mice have a sharp 
increase in average peripheral blood WBC count prior to a cluster of deaths 
Average WBC count (K/μL) in peripheral blood of mice.  
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Time-limited PI3Kδ inhibition does not alter the ultimate course of disease in gain-of-
function mutant Shp2-expressing mice 
Whenever possible, moribund mice were euthanized for analysis to assess the 
cause of death. Although the PI3Kδ inhibitor-treated animals demonstrated prolonged 
survival, at the time of euthanasia, these animals demonstrated similar levels of 
splenomegaly and elevated peripheral leukocyte counts compared to the vehicle-
treated animals (Figure 3.10). Furthermore, composition of the bone marrow and spleen 
in moribund animals was not significantly different between the two groups (Figures 
3.11 and 3.12). Most animals in both groups succumbed to a myeloid disease; however, 
both groups did demonstrate the emergence of T cell leukemia in a small number of 
mice, indicated by elevated levels of CD4+CD8+ cells in the bone marrow and spleen. 
Taken together, these findings suggest that time-limited PI3Kδ inhibition delays 
mortality due to Shp2-induced leukemia, but does not alter the ultimate course of 
disease. These findings imply that PI3Kδ activity resumes after termination of treatment 
and that continued or intermittent inhibition may be needed for optimal treatment of 
disease. 
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Figure 3.10: Vehicle- and PI3Kδ inhibitor-treated Shp2E76K/+;LysMcre+ mice have no 
differences in degree of splenomegaly or leukocytosis when moribund 
(A) Average spleen to body weight percentage at the time of death, n=14 for vehicle 
group, n=12 for PI3Kδ inhibitor group. (B) Average WBC count (K/μL) in peripheral blood 
at the time of death, n=9 for vehicle group, n=6 for PI3Kδ inhibitor group. 
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Figure 3.11: Vehicle- and PI3Kδ inhibitor-treated Shp2E76K/+;LysMcre+ mice have no 
differences in terminally differentiated hematopoietic cell populations in the bone 
marrow when moribund 
Percentage of bone marrow myeloid cells (Gr1+Mac1+), B cells (B220+), and T cells 
(CD4+CD8+) at the time of death, gated on live events. n=13 for vehicle group, n=8 for 
PI3Kδ inhibitor group. 
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Figure 3.12: Vehicle- and PI3Kδ inhibitor-treated Shp2E76K/+;LysMcre+ mice have no 
differences in terminally differentiated hematopoietic cell populations in the spleen 
when moribund 
Percentage of spleen myeloid cells (Gr1+Mac1+), B cells (B220+), and T cells (CD4+CD8+) 
at the time of death, gated on live events. n=13 for vehicle group, n=8 for PI3Kδ 
inhibitor group. 
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Discussion 
We previously found that genetic and pharmacologic inhibition of PI3K p110δ in 
vitro normalizes hypersensitivity to GM-CSF and reduces GM-CSF-stimulated 
hyperproliferation of GOF Shp2-expressing murine and human cells (Goodwin, Li 2014). 
We now demonstrate that in vivo inhibition of PI3K p110δ increases the survival of GOF 
Shp2-expressing mice. One notable observation was increased terminally differentiated 
myeloid cells (Gr1+Mac1+) in the peripheral blood of PI3Kδ inhibitor-treated animals 
(Figure 3.6). A potential explanation for this observation is the recently-appreciated role 
of PI3K p110δ in regulatory T cell function with the resulting disruption of the protective 
tumor cell microenvironment and peripheral distribution of tumor cells upon PI3K 
p110δ inhibition (Fruman, Chiu 2017).  In the context of this JMML model, it is possible 
that PI3K p110δ inhibition leads to redistribution and increased differentiation of 
mutant myeloid cells.   
In both the vehicle- and PI3Kδ inhibitor-treated animals, we observed increased 
peripheral blood WBC counts that temporally preceded a precipitous drop in survival 
(Figures 3.8 and 3.9). The WBC spike in the PI3Kδ inhibitor-treated animals was more 
pronounced than that observed in the vehicle-treated group (Figure 3.9). One possibility 
accounting for this difference is that we simply “missed” a similarly high spike in the 
vehicle-treated mice, which might have occurred between the 18 week and 24 week 
scheduled blood draws (Figure 3.9). An alternative explanation is that treatment with 
the PI3K p110δ inhibitor allowed animals to tolerate higher circulating WBC counts 
before succumbing to disease. 
67 
 As the armamentarium of molecularly targeted therapies continues to grow, 
potential application to difficult-to-treat diseases such as JMML is a valuable priority. 
Previous work conducted in the Braun lab demonstrated that treatment of GOF Kras- 
and GOF Nras-expressing mice with the pan-PI3K inhibitor, GDC-0941, or the allosteric 
Akt inhibitor, MK-2206, effectively ameliorated hyperactive Ras-induced disease 
(Akutagawa, Huang 2016). The effectiveness of single pathway inhibition is likely limited, 
as drug resistance to PI3K/Akt inhibition can develop due to aberrant upregulation of 
the Ras-Erk pathway. However, an analysis of clinical trials found that patients receiving 
Ras/MEK/Erk pathway inhibitors combined with pan-PI3K inhibitors commonly 
experienced toxic adverse effects (Shimizu, Tolcher 2012). The differential and 
potentially more limited side effect profile of PI3Kδ inhibition compared to pan-PI3K 
inhibition (Brown, Byrd 2014, Fruman, Chiu 2017) may provide a therapeutic window to 
simultaneously target both the Ras-Erk and PI3K-Akt pathways in the treatment of 
JMML. There is a clear need for improved chemotherapeutic treatments for JMML, as 
the current treatment options are limited with only variable efficacy. This work supports 
the rationale of using PI3Kδ inhibitors in the treatment of patients with JMML and 
possibly other myeloid cell malignancies. 
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CHAPTER FOUR 
PHARMACOLOGIC INHIBITION OF BTK AND OF PI3K p110δ COOPERATE TO REDUCE 
GAIN-OF-FUNCTION MUTANT SHP2-INDUCED GM-CSF HYPERSENSITIVITY AND THE 
DEVELOPMENT OF MYELOID LEUKEMIA 
Introduction 
 Having shown the effectiveness of PI3K p110δ inhibition in correcting gain-of-
function mutant Shp2-induced leukemia phenotypes in vitro and in prolonging survival 
of mice in vivo, we next wanted to explore signaling molecules with which p110δ may 
be interacting to promote the aberrant Shp2 signaling in myeloid cells. In recent years, a 
key player in B cell receptor (BCR) signaling, Bruton’s tyrosine kinase (BTK), has come 
under intense study in the field of lymphocytic leukemia and lymphoma research. 
Ibrutinib, a small molecule inhibitor targeting BTK, has proven to be very effective and 
has received FDA-approval for the treatment of a variety of B cell malignancies, 
including mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström’s 
macroglobulinemia, and marginal zone lymphoma (Barr, Robak 2016, Burger, Tedeschi 
2015, Byrd, Brown 2014, Dimopoulos, Trotman 2017, Dreyling, Jurczak 2016, Noy, Vos 
2016). 
 BTK’s main function is to promote normal B cell development, as demonstrated 
by individuals with the disease X-linked agammaglobulinemia (XLA), who have 
inactivating mutations in BTK and lack mature B lymphocytes due to failure of 
immunoglobulin heavy chain rearrangement. Therefore, up until this point, all research 
on BTK has focused on B cell malignancies. However, although XLA patients have no 
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deficiencies beyond those affecting the B cell-mediated immune system response, BTK 
expression is not limited solely to the B cell lineage. BTK is also highly expressed in 
myeloid cells, and mice lacking BTK are defective in many myeloid cell functions, such as 
the generation of reactive oxygen species by macrophages (Mangla, Khare 2004). 
Furthermore, BTK has been found to be highly expressed and phosphorylated in AML 
patient samples (Rushworth, Murray 2014). Thus, it is possible that BTK signaling may 
also play an important role in myeloid malignancies, such as JMML. 
Following antigen-mediated BCR cross-linking and activation, BTK is 
phosphorylated by spleen tyrosine kinase (SYK) and, once activated, signals downstream 
to phospholipase C γ2 (PLCγ2), protein kinase C (PKC), and ERK for proper B cell 
development and maturation (Hashimoto, Okada 1998, Kim, Sekiya 2004). BTK 
activation depends on its recruitment to the plasma membrane by PI(3,4,5)P3, the 
phospho-lipid product of PI3K p110δ. Thus, it has been hypothesized that dual inhibition 
with a BTK and a p110δ inhibitor may have an additive effect in the treatment of CLL 
(Brown 2014). In line with this notion, Acerta Pharma is currently recruiting for a phase I 
clinical trial to test the combination of a second-generation BTK inhibitor (ACP-196) with 
a specific p110δ inhibitor (ACP-319) in B cell malignancies (NCT02328014). ACP-196, also 
called acalabrutinib and marketed under the name Calquence, is FDA approved for the 
treatment of relapsed mantle cell lymphoma. Given the collaboration of BTK and p110δ 
in BCR signaling, the key role of p110δ in GOF Shp2-induced leukemia, and the high 
expression of BTK in myeloid cells, we hypothesized that BTK and p110δ function 
cooperatively in GOF Shp2-expressing myeloid cells to promote MPN. To test this 
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hypothesis, we examined the potential collaboration of GM-CSF-stimulated BTK and 
p110δ in GOF Shp2-expressing myeloid cells and tested the inhibitor combination in vivo 
in mice to test their effectiveness for correcting leukemia phenotypes and increasing 
survival. 
For these studies, we used ACP-196 (BTK inhibitor) and ACP-319 (p110δ 
inhibitor), which were generously provided to us by Acerta Pharma. For the in vitro 
studies, we utilized bone marrow low-density mononuclear cells (LDMNCs) from 
Shp2E76K/+;LysMcre+ mice, which express the most common and active SHP2 mutation 
(E76K) conditionally in cells of the myeloid lineage (Xu, Liu 2011) or from polyI:polyC-
treated Shp2D61Y/+;Mx1-cre+ mice (Chan, Kalaitzidis 2009). For the in vivo experiments, 
we used ACP-196 and ACP-319 either singly or in combination to treat 
Shp2E76K/+;LysMcre+ mice between 12 and 20 weeks of age to allow sufficient time for 
the development of disease prior to the initiation of therapy. We predicted that the 
treatment of GOF Shp2-expressing myeloid cells with ACP-196 and ACP-319 would 
reduce progenitor cell hyperproliferation and hyperphosphorylation of Akt and Erk in 
response to GM-CSF stimulation. We further predicted that the combination of 
inhibitors would correct leukemia features, such as splenomegaly and leukocytosis, and 
prolong the overall survival of Shp2E76K/+;LysMcre+ mice. 
 
Results 
BTK is hyperactivated in gain-of-function mutant Shp2 expressing macrophages and is 
downstream of PI3K p110δ in myeloid cell signaling 
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 BTK’s role in malignancies has previously only been studied in B cell leukemia 
and lymphoma. Therefore, we initially performed an experiment to determine if BTK is 
hyperactivated in mutant Shp2 myeloid cells. We isolated LDMNCs from the bone 
marrow of Shp2D61Y/+;Mx1-cre+ mice 8-12 weeks after polyI:polyC treatment to allow for 
disease onset. The cells were cultured in media containing 25ng/mL of macrophage 
colony-stimulating factor (M-CSF) for 1 week to generate bone marrow-derived 
macrophages. Once fully differentiated, the macrophages were starved overnight, 
treated for 1 hour with 0ng/mL or 10ng/mL of GM-CSF, and lysed for immunoblot 
analysis. We found that BTK was indeed hyperphosphorylated in the Shp2D61Y-
expressing cells compared to WT Shp2, both with and without GM-CSF stimulation 
(Figure 4.1). Furthermore, we also observed increased phosphorylation of BTK’s known 
downstream target in B cell receptor signaling, PLCγ2, at two different tyrosine 
phosphorylation sites in the GOF Shp2-expressing macrophages (Figure 4.1). 
 Knowing that BTK is hyperactivated in GOF Shp2-expressing macrophages, we 
next tested the hypothesis that BTK is activated downstream of p110δ in the GM-CSF-
stimulated signaling pathway using the BTK and p110δ inhibitors. We treated bone 
marrow-derived macrophages from Shp2E76K/+;LysMcre+ mice with GM-CSF (0ng/mL or 
10ng/mL) and ACP-196 (0.05uM or 0.1uM) or ACP-319 (0.5uM or 1uM) or no inhibitor at 
all, followed by examination of BTK and PLCγ2 phosphorylation levels via immunoblot. 
We saw, as expected, a dose-dependent decrease in BTK phosphorylation at Y223, the 
autophosphorylation site, when treated with the BTK inhibitor (Figure 4.2, compare 
lanes 2, 3, and 4). More interestingly, there was likewise a dose-dependent reduction in 
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Figure 4.1: BTK and PLCγ2 are hyperphosphorylated in gain-of-function mutant Shp2-
expressing macrophages 
Immunoblot analysis of phospho- and total BTK and PLCγ2 protein levels in bone 
marrow-derived macrophages from WT Shp2 and Shp2D61Y-expressing mice in the 
absence and presence of 10ng/mL GM-CSF. 
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phospho-BTK with the p110δ inhibitor, indicating that p110δ does function as an 
upstream activator of BTK (Figure 4.2, compare lanes 2, 5, and 6). This finding is 
consistent with the known BCR-stimulated signaling pathway in B cells, where PI3K’s 
phospholipid product PI(3,4,5)P3 recruits BTK to the plasma membrane by BTK’s 
Plekstrin Homology domain to facilitate its phosphorylation (Bradshaw 2010). However, 
notably unlike the BCR signaling pathway, neither inhibitor had any effect on the levels 
of phospho-PLCγ2 at Y759 or Y1217, two tyrosine phosphorylation sites known to be 
direct BTK targets in B cells. 
 Next, we wished to test if the BTK and p110δ inhibitors reduced GM-CSF-induced 
hyperphosphorylation of Akt and Erk. We again treated bone marrow-derived 
macrophages with GM-CSF (0ng/mL or 10ng/mL) and two different concentrations of 
ACP-319 (0.1uM and 0.5uM), and also included the presence or absence of 0.05uM ACP-
196 for each condition. Upon treatment with the p110δ inhibitor ACP-319, similar to 
that observed with GS-9820 (Goodwin, Li 2014), there was a dose dependent decrease 
in phospho-Akt and phospho-Erk (Figure 4.3, compare lanes 2, 3, and 4). With the BTK 
inhibitor alone at the 0.05uM dose, we observed only modest reductions in Akt and Erk 
phosphorylation (Figure 4.3, compare lanes 2 and 5). However, when ACP-319 was 
added to this dose of ACP-196, there was a pronounced reduction in both phospho-Akt 
and –Erk compared to either the same dose of ACP-319 or ACP-196 alone (Figure 4.3, 
compare lanes 3 and 4 to lanes 6 and 7, or lane 5 to lanes 6 and 7, respectively). These 
findings demonstrate that BTK cooperates with p110δ in promoting the hyperactivation 
of Akt and Erk in GOF Shp2-expressing macrophages and strengthens the idea that dual 
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Figure 4.2: Inhibition of BTK and p110δ independently decrease BTK phosphorylation 
in a dose-dependent manner in gain-of-function mutant Shp2-expressing 
macrophages 
Immunoblot showing phospho- and total BTK and PLCγ2 protein levels in Shp2E76K-
expressing bone marrow-derived macrophages in the absence or presence of 10ng/mL 
GM-CSF and the indicated concentrations of BTK and p110δ inhibitor. 
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Figure 4.3: Inhibition of BTK and p110δ independently decrease Akt and Erk 
phosphorylation in a dose-dependent manner in gain-of-function mutant Shp2-
expressing macrophages 
Immunoblot showing phospho- and total Akt and Erk protein levels in Shp2D61Y-
expressing bone marrow-derived macrophages in the absence or presence of 10ng/mL 
GM-CSF and the indicated concentrations of BTK and p110δ inhibitor. 
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inhibition may be effective for myeloid malignancies. Along with data presented in 
Figure 4.2, which show that p110δ and BTK inhibition both fail to reduce phospho-PLCγ2 
levels, these findings highlight the novel observation that p110δ and BTK positively 
signal to Erk and Akt in a PLCγ2-independent manner in GOF Shp2-expressing myeloid 
cells. 
 
Inhibition of BTK and PI3K p110δ cooperatively reduce GM-CSF-stimulated 
hyperproliferation in bone marrow progenitor cells from gain-of-function mutant Shp2 
expressing mice 
 With the signaling pathway of p110δ to BTK demonstrated to be intact in 
myeloid cells, we next went on to test the effectiveness of the Acerta Pharma p110δ 
and BTK inhibitors at reducing GM-CSF-stimulated hyperproliferation in vitro. We 
isolated bone marrow LDMNCs from Shp2E76K/+;LysMcre- or Shp2E76K/+;LysMcre+ mice and 
performed [3H]-thymidine incorporation assays to measure proliferation in the presence 
of 10ng/mL of GM-CSF. While 1uM and 5uM of ACP-319 induced a dose-dependent 
decrease in cell proliferation, ACP-196 at concentrations of 1uM and 5uM had no effect 
on cell proliferation (Figure 4.4). However, there was a significantly greater reduction in 
proliferation when 5uM of ACP-319 was combined with 1uM of ACP-196 compared to 
that of 5uM ACP-319 alone (Figure 4.4). These proliferation data are consistent with the 
results of the biochemical studies, where we observed only a modest reduction in Akt or 
Erk phosphorylation in response to ACP-196 treatment alone, but a cooperative effect in  
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Figure 4.4: Proliferation is cooperatively decreased by BTK and p110δ dual inhibition 
in bone marrow LDMNCs from Shp2E76K;LysMcre+ mice 
WT Shp2 and E76K-expressing murine bone marrow LDMNCs were subjected to [3H]-
thymidine incorporation assays in the presence of 1ng/mL GM-CSF, n=4 independent 
experiments, *p<0.05 for E76K treated with 1μM or 5μM ACP-319 compared to E76K 
untreated, **p<0.05 for E76K treated with 5μM ACP-319 plus 1μM ACP-196 compared 
to E76K treated with 5μM ACP-319 alone and compared to E76K treated with 1μM ACP-
196 alone, statistical analyses performed using unpaired, two-tailed, Student’s t-test. 
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response to the combination of ACP-196 with ACP-319 (Figure 4.3). This finding provides 
further evidence that dual inhibition of p110δ and BTK is a viable strategy in the 
treatment of mutant Shp2-induced myeloid leukemia. 
 
Pharmacologic inhibition of BTK and PI3K p110δ in vivo using 15mg/kg of ACP-196 and 
15mg/kg of ACP-319 trends towards prolonged survival in gain-of-function mutant Shp2-
expressing mice 
 With the promising performance of the combination of ACP-196 plus ACP-319 in 
vitro, our next step was to treat Shp2E76K/+;LysMcre+ mice with these inhibitors in vivo. 
Twelve mice were assigned to each of four different treatment groups: vehicle (0.5% 
w/v methylcellulose + 0.1% v/v Tween 80), 15mg/kg ACP-196, 15mg/kg ACP-319, and 
15mg/kg ACP-196 plus 15mg/kg ACP-319. The average ages of each group at the start of 
treatment, respectively, were 146 days, 141 days, 136 days, and 141 days. There were 
six females and six males in each group except for the vehicle group, which had five 
females and seven males. The dosing protocol was previously tested in mice and 
recommended by collaborators at Acerta Pharma (Dr. Cecile Krejsa, personal 
communication). After completion of treatment, these 48 mice were followed for 
overall survival. 
 We observed no differences in survival after treatment with either ACP-196 or 
ACP-319 alone, with these survival curves overlapping with and often crossing that of 
the vehicle group (Figure 4.5). In contrast, the drug combination-treated mice 
demonstrated an improved survival compared to the other three treatment groups, and  
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Figure 4.5: BTK and p110δ dual inhibitor-treated Shp2E76K/+;LysMcre+ mice show a 
trend towards prolonged survival compared to vehicle-treated and single agent-
treated mice  
Kaplan-Meier survival curve of days elapsed from start of treatment until death, n=12 
per treatment group, p=0.112 comparing survival after treatment for BTK plus p110 
inhibitor-treated mice and vehicle-treated mice, statistical analyses performed by log-
rank (Mantel-Cox) test. 
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Figure 4.6: Vehicle-, BTK inhibitor-, and p110δ inhibitor-treated Shp2E76K/+;LysMcre+ 
mice have no differences in degree of splenomegaly or leukocytosis when moribund 
(A) Average spleen to body weight percentage at the time of death; n=10 for Veh, Veh; 
n=8 for ACP-196, Veh; n=8 for Veh, ACP-319; n=7 for ACP-196, ACP-319. (B) Average 
WBC count (K/μL) in peripheral blood at the time of death; n=6 for Veh, Veh; n=5 for 
ACP-196, Veh; n=6 for Veh, ACP-319; n=3 for ACP-196, ACP-319. 
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its curve never crossed the vehicle group curve (Figure 4.5). However, the difference in 
survival was not statistically significant, with a logrank p-value of 0.112 comparing the 
ACP-196 plus ACP-319 group to the vehicle group. Every effort was made to analyze the 
mice in this survival study as they became moribund. We did not observe any 
differences in spleen to body weight percentage or peripheral blood WBC values 
between any of the four groups (Figure 4.6). There was also no change in the bone 
marrow, spleen, or peripheral blood populations of myeloid cells, B cells, or T cells (data 
not shown). 
 
Pharmacologic inhibition of BTK and PI3K p110δ in vivo using 15mg/kg of ACP-196 and 
15mg/kg of ACP-319 elicited a modest reduction in splenomegaly and leukocytosis in 
gain-of-function mutant Shp2-expressing mice 
 Another cohort of four Shp2E76K/+;LysMcre+ mice in each treatment group were 
treated in the same manner as described above. The average ages at the start of 
treatment were as follows: vehicle = 120 days, ACP-196 = 117 days, ACP-319 = 117 days, 
ACP-196 plus ACP-319 = 119 days. Each group had three males and one female except 
for the ACP-319 group, which consisted of one male and three females. All sixteen mice 
were euthanized on the morning directly following administration of the final drug dose 
in order to analyze the extent of disease progression. 
With the 15mg/kg combination drug dose, we observed favorable but non-
significant trends in several measures of leukemia. The spleen to body weight 
percentage was unchanged by administration of ACP-196 alone, but there was a small 
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decrease in the ACP-319 group and a greater decrease in the dual inhibitor-treated 
group of mice (Figure 4.7). The combination-treated mice also had the greatest 
reduction in peripheral blood WBC count, as calculated by subtracting the WBC count 
immediately before beginning treatment from the WBC count immediately before 
euthanasia (Figure 4.8). 
We analyzed the hematopoietic stem/progenitor cells (lineage-Sca1+cKit+, LSK), 
granulocyte monocyte progenitors (GMP, CD34+CD16/32+), common myeloid 
progenitors (CMP, CD34+CD16/32-), megakaryocyte erythrocyte progenitors (MEP, 
CD34-CD16/32-), and the SLAM marker populations of hematopoietic stem cells (HSC, 
CD150+CD48-), multipotent progenitor cells (MPP, CD150-CD48-), and lineage-restricted 
progenitor cells (LRP, CD150-CD48+). We found no significant changes in the bone 
marrow, spleen, or peripheral blood of the mice for these stem/progenitor populations 
(data not shown). Consistent with no changes in the phenotypically-defined progenitor 
populations, we found no differences in the GM-CSF hypersensitivity of the bone 
marrow hematopoietic progenitors from the drug-treated mice in methylcellulose 
colony-forming assays (data not shown). 
The terminally differentiated hematopoietic cell populations were also analyzed 
in each of these three hematopoietic compartments. The B220+ B cells and CD4+CD8+ T 
cells were unchanged among the four treatment groups; however, we found that the 
Gr1+Mac1+ myeloid cells were significantly increased in the peripheral blood of the ACP-
319-treated and trended higher in the ACP-196 + ACP-319-treated groups (Figure 4.9). 
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Figure 4.7: Dual inhibition of BTK and p110δ in vivo trends towards decreased 
splenomegaly in Shp2E76K/+;LysMcre+ mice 
The spleen to body weight ratio of mice at the end of 21 days of 15mg/kg treatment, 
n=4 per group, p=0.1742 comparing the BTK plus p110δ inhibitor-treated mice to 
vehicle-treated mice, statistical analyses performed by unpaired, two-tailed, Student’s t-
test. 
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Figure 4.8: BTK and p110δ dual inhibition in vivo trends towards a reduction in 
peripheral blood WBC count in Shp2E76K/+;LysMcre+ mice 
The average values of peripheral blood WBC count prior to treatment subtracted from 
the WBC count at the end of 21 days of 15mg/kg treatment, n=4 mice per group. 
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Figure 4.9: BTK and p110δ dual inhibition in vivo trends towards increased terminally 
differentiated myeloid cells in the peripheral blood of Shp2E76K/+;LysMcre+ mice 
Average percentage of peripheral blood myeloid cells (Gr1+Mac1+) gated on live events, 
n=4 per treatment group, *p=0.004 comparing the percentage of myeloid cells in the 
peripheral blood of 15mg/kg ACP-319-treated mice to vehicle-treated mice, p=0.065 
comparing the percentage of myeloid cells of 15mg/kg ACP-196 + ACP-319-treated mice 
to vehicle-treated mice, statistical analyses performed by unpaired, two-tailed, 
Student’s t-test. 
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Pharmacologic inhibition of BTK and PI3K p110δ in vivo using 20mg/kg of ACP-196 and 
20mg/kg of ACP-319 significantly reduced splenomegaly and leukocytosis in gain-of-
function mutant Shp2-expressing mice 
 Because we had observed promising trends in the 15mg/kg drug combination 
group, we sought to determine if increasing the dose of each drug to 20mg/kg would 
produce a greater normalization of leukemic parameters. We focused on the ACP-196 
plus ACP-319 combination because neither ACP-196 alone nor ACP-319 alone induced 
favorable trends compared to the vehicle group. The ACP-196 inhibitor had previously 
been tested at this higher concentration, but ACP-319 had never been used above 
15mg/kg (Dr. Cecile Krejsa, personal communication). Therefore, we closely observed 
the mice each day during treatment and were prepared to scale back the dosing of one 
or both inhibitors if any signs of toxicity developed. However, the mice appeared 
healthy throughout the entire course of treatment, with no major changes in weight or 
activity level. We treated seven Shp2E76K/+;LysMcre+ mice per group (vehicle or ACP-196 
plus ACP-319) for 21 days BID via oral gavage. The vehicle group had an average age of 
129 days and the drug combination group had an average age of 125 days at the start of 
treatment. Both groups consisted of four females and three males each. At the end of 
the 21 days, the fourteen mice were euthanized for analysis. 
 With the increased dose of 20mg/kg of each drug, there was a significant 
reduction in splenomegaly compared to the vehicle-treated mice (Figure 4.10). Prior to 
treatment, the peripheral blood WBC count was not significantly different between the 
two groups, but the treatment group was slightly higher than the vehicle group (Figure 
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Figure 4.10: BTK and p110δ dual inhibition in vivo decreases splenomegaly in 
Shp2E76K/+;LysMcre+ mice 
The spleen to body weight ratio of mice at the end of 21 days of treatment with 
20mg/kg of inhibitors, n=7 per group, *p=0.0053 comparing the inhibitor-treated mice 
to vehicle-treated mice, statistical analyses performed by unpaired, two-tailed, 
Student’s t-test. 
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4.11A). After the completion of treatment, however, the ACP-196 plus ACP-319 treated 
mice had significantly lower WBC count (Figure 4.11B). 
 We also phenotypically characterized the composition of the cell populations in 
the bone marrow, spleen, and peripheral blood by flow cytometry analysis. Similar to 
what we observed with GS-9820 treatment (Chapter Three, Figure 3.3), the LSK cells 
were significantly reduced in the bone marrow of the inhibitor-treated mice (Figure 
4.12). For the hematopoietic progenitor populations, we found no significant differences 
in the CMPs, GMPs, or MEPS (data not shown) or in the frequency of the HSC, MPP, and 
LRP populations as determined by SLAM markers (data not shown). Regarding the 
terminally differentiated myeloid cells, B cells, and T cells, the frequencies were the 
same between treatment groups in the bone marrow (Figure 4.13) and spleen 
compartments (Figure 4.14). However, the peripheral blood had significantly more 
terminally differentiated myeloid cells and fewer B cells in the drug-treated mice 
compared to vehicle (Figure 4.15). These findings suggest that the combination of BTK 
and p110δ inhibition promote myeloid differentiation and mobilization of mature 
myeloid cells into the peripheral circulation. The decreased peripheral blood B cell 
population is likely due to the action of BTK inhibition, as B cell differentiation and 
maturation is a well-documented function of BTK. 
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Figure 4.11: BTK and p110δ dual inhibition in vivo decreases peripheral blood WBC 
count in Shp2E76K/+;LysMcre+ mice 
(A) The average values of peripheral blood WBC count in vehicle group and treatment 
group prior to treatment. (B) The average values of peripheral blood WBC count in 
vehicle-treated and 20mg/kg inhibitor-treated mice at the end of 21 days of treatment, 
n=7 per group, *p=0.0221 comparing the inhibitor-treated mice to vehicle-treated mice, 
statistical analyses performed by unpaired, two-tailed, Student’s t-test. 
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Figure 4.12: BTK and p110δ dual inhibition in vivo decreases Lin-Sca1+Kit+ progenitor 
cells in the bone marrow of Shp2E76K/+;LysMcre+ mice 
Average percentage of Lin-Sca1+Kit+ (LSK) cells in bone marrow (BM), spleen (SP), and 
peripheral blood (PB), n=7 per group, *p=0.0114 comparing LSK cells in the bone 
marrow of 20mg/kg inhibitor-treated mice to vehicle-treated mice, statistical analyses 
performed by unpaired, two-tailed, Student’s t-test. 
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Figure 4.13: BTK and p110δ dual inhibition in vivo does not affect terminally 
differentiated hematopoietic cell populations in the bone marrow of 
Shp2E76K/+;LysMcre+ mice 
Average percentage of bone marrow myeloid cells (Gr1+Mac1+), B cells (B220+), and T 
cells (CD4+CD8+) gated on live events, n=7 per treatment group. 
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Figure 4.14: BTK and p110δ dual inhibition in vivo does not affect terminally 
differentiated hematopoietic cell populations in the spleen of Shp2E76K/+;LysMcre+ 
mice 
Average percentage of spleen myeloid cells (Gr1+Mac1+), B cells (B220+), and T cells 
(CD4+CD8+) gated on live events, n=7 per treatment group. 
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Figure 4.15: BTK and p110δ dual inhibition in vivo increases terminally differentiated 
myeloid cells and decreases B cells in the peripheral blood of Shp2E76K/+;LysMcre+ mice 
Average percentage of peripheral blood myeloid cells (Gr1+Mac1+), B cells (B220+), and T 
cells (CD4+CD8+) gated on live events, n=7 per treatment group, *p=0.0002 comparing 
the percentage of myeloid cells in the peripheral blood of 20mg/kg inhibitor-treated 
mice to vehicle-treated mice, *p=0.0015 comparing the percentage of B cells in the 
peripheral blood of 20mg/kg inhibitor-treated mice to vehicle-treated mice, statistical 
analyses performed by unpaired, two-tailed, Student’s t-test. 
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Discussion 
 In recent years, BTK has emerged as a target of intense interest in the field of 
lymphoid malignancies. Because it was identified as the defective protein in X-linked 
agammaglobulinemia in 1993, much is already known about BTK’s structure and its 
signaling in the context of the B cell receptor. For example, it is known to be 
phosphorylated after BCR cross-linking, and its activation is promoted by recruitment to 
the plasma membrane by PI(3,4,5)P3, which is produced by PI3K. Beyond BCR signaling, 
there have been some suggestions that BTK plays a role in myeloid diseases as well. 
Thus, BTK came to our attention as a possible signaling molecule that may cooperate 
with p110δ to promote GOF Shp2-induced myeloid leukemia. 
 First, we evaluated the importance of BTK in GM-CSF-stimulated signaling in GOF 
Shp2-expressing myeloid cells. We found that BTK activation is upregulated in GOF 
Shp2-expressing bone marrow-derived macrophages compared to WT Shp2 (Figure 4.1). 
We were then able to verify that the p110δ-to-BTK signaling pathway was intact by 
showing that inhibition of p110δ caused a dose-dependent decrease in BTK 
phosphorylation (Figure 4.2). We also demonstrated that, while BTK inhibition alone 
only modestly induced signaling changes, the inhibition of BTK and p110δ together 
cooperatively reduced the phosphorylation of Akt and Erk in GOF Shp2-expressing 
macrophages in response to GM-CSF stimulation (Figure 4.3). Consistent with these 
biochemical results, BTK inhibition alone did not affect proliferation of Shp2E76K-
expressing bone marrow LDMNCs in [3H]-thymidine incorporation assays, but it 
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cooperated with p110δ inhibition to further reduce hyperproliferation in response to 
GM-CSF (Figure 4.4).  
 Next we moved our studies with the BTK and p110δ inhibitors to 
Shp2E76K;LysMcre+ mice in vivo. We initially used 15mg/kg of each inhibitor and saw 
promising but statistically non-significant trends in prolonged survival and decreased 
leukemia progression compared to vehicle treatment (Figures 4.5-4.9). Therefore, we 
repeated our experiments using the increased dose of 20mg/kg of each inhibitor. With 
the increased dosing, there was significantly reduced splenomegaly and leukocytosis in 
the treatment group versus the vehicle group (Figures 4.10-4.11). We also found fewer 
bone marrow LSK progenitor cells and a corresponding increase in mature myeloid cells 
in the peripheral blood (Figures 4.12 and 4.15). These findings are consistent with what 
we have seen using the other p110δ inhibitor, GS-9820, administered at 30mg/kg 
(Chapter Three, Figures 3.1, 3.3, and 3.6). A probable explanation for this shift in cell 
populations is due to p110δ and/or BTK inhibition causing a disruption in the bone 
marrow tumor cell niche and inducing myeloid cell maturation. We also saw significantly 
decreased terminally differentiated B cells in the peripheral blood (Figure 4.15). This 
observation is likely due to the inhibition of BTK signaling, which has been well-
documented to be crucial for normal B cell differentiation and maturation. 
The first generation BTK inhibitor ibrutinib has had great success in a variety of B 
cell leukemias and lymphomas ever since its accelerated FDA approval in 2013 for 
relapsed mantle cell lymphoma. However, it also has significant activity against a 
number of other kinases, leading to side effects and discontinuation in patients. Second-
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generation BTK inhibitors, such as acalabrutinib (ACP-196), bring the promise of having 
the same effectiveness as ibrutinib but fewer side effects and reduced toxicity. We have 
shown in our pre-clinical mouse model that ACP-196 effectively blocks the 
phosphorylation of BTK in bone marrow-derived macrophages. Another problem that 
has arisen during ibrutinib treatment is the development of resistance, which is an 
inherent drawback of many monotherapies. The idea of using combined BTK and p110δ 
inhibition has been proposed for the treatment of B cell malignancies, and clinical trials 
to test such a strategy have already begun. Our studies show that ACP-196 can 
cooperate with the p110δ inhibitor, ACP-319, to correct GM-CSF hypersensitivity in vitro 
and to decrease leukemia progression in vivo. A drug combination strategy is 
advantageous because it allows a lower dose of each drug to be used to attain high 
efficacy with less risk of toxicity. This concept is demonstrated in our studies by the 
similar responses we observed in the Shp2E76K;LysMcre+ mice after in vivo treatment 
with 30mg/kg of GS-9820 compared with 20mg/kg each of ACP-319 plus ACP-196. 
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CHAPTER FIVE 
BCAP IS HYPERPHOSPHORYLATED AND CONNECTS BTK SIGNALING TO PI3K IN GAIN-OF-
FUNCTION MUTANT SHP2-EXPRESSING MYELOID CELLS  
Introduction 
With the importance of BTK established in gain-of-function (GOF) Shp2-induced 
myeloid leukemia, we wished to further explore the mechanism of how BTK promotes 
leukemogenesis. We were intrigued by our finding that, unlike in BCR signaling, neither 
the BTK inhibitor nor the p110δ inhibitor changed the levels of phospho-PLCγ2 in bone 
marrow-derived macrophages (Chapter Four, Figure 4.2). PLCγ2 is the known 
downstream direct target of BTK in B cell receptor (BCR) signaling that connects BTK to 
Erk activation. Thus, although BTK inhibition cooperated with p110δ inhibition to further 
decrease both Erk and Akt phosphorylation compared to p110δ inhibition alone in GOF 
Shp2-expressing myeloid cells, the effect of BTK inhibition appeared to be independent 
of phospho-PLCγ2. Therefore, we were interested in finding how, if not by way of 
phospho-PLCγ2, BTK may be signaling in order to promote GM-CSF-stimulated Akt and 
Erk phosphorylation and hyperproliferation in GOF Shp2-expressing myeloid cells. 
In the literature on BCR signaling, we found that another direct target of BTK 
phosphorylation is B cell adaptor for PI3K (BCAP). The mouse BCAP protein has three 
YxxM motifs that, once phosphorylated, bind to proteins at their SH2 domains. A known 
binding target of phospho-BCAP is PI3K, specifically the N-SH2 domain of the p85α 
regulatory subunit. In fact, BCAP was first discovered as a novel protein that binds to the 
N-terminal SH2 domain of p85α from chicken DT40 B cells (Okada, Maeda 2000). This 
98 
BCAP-p85α association promotes PI3K activity both by increasing the PI3K catalytic 
domain’s kinase activity and by recruiting PI3K to the plasma membrane where it can 
access its substrate, PI(4,5)P2 (Fruman, Snapper 1999). Thus, BCAP facilitates the 
activation of Akt via the canonical PI3K-Akt pathway, as well as Erk activation by cross-
talk between signaling pathways. 
There are four different protein isoforms of BCAP encoded by the Pik3ap1 gene 
by way of alternative splicing and posttranslational modification mechanisms. The full-
length transcript, BCAP-L, has been found to be more important than the truncated 
BCAP-S for PI3K activation in myeloid cells. In a study of BCAP’s ability to activate PI3K in 
the context of toll-like receptor signaling, Ni et. al used bone marrow-derived 
macrophages lacking Syk expression, as Syk is another molecule known to be activated 
by BCR signaling and functions to activate BCAP in B cells. Ni et. al made the surprising 
observation of increased BCAP phosphorylation in these Syk-/- macrophages, which is 
the opposite of what occurs in B cells. In the bone marrow-derived macrophages, the 
increase in phosphorylation occurred specifically in the two full-length BCAP isoforms, 
which led to more BCAP association with p85α as visualized by co-immunoprecipitation. 
Furthermore, the authors found that the isolated membrane fraction from macrophages 
stimulated with lipopolysaccharide (LPS) also demonstrated the full-length BCAP 
isoforms being specifically phosphorylated (Ni, MacFarlane 2012).  
After B cells, the cells with the second highest expression levels of BCAP are 
macrophages (Okada, Maeda 2000). Several studies, including the above-mentioned 
one by Ni et. al, have recently been published that provide evidence that BCAP plays an 
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important role in myeloid cells as well as B cells. A phosphoproteomics screen using Btk-
/-Tec-/- bone marrow-derived macrophages found decreased phosphorylation in several 
proteins, including BCAP (Tampella, Kerns 2015). Since BCAP’s ability to activate PI3K 
and Akt has been well-documented in B cells (Castello, Gaya 2013, Qin and Chock 2003), 
and because Tampella et. al identified BCAP as being activated downstream of BTK in 
bone marrow-derived macrophages, we hypothesized that BCAP may be the connecting 
molecule between BTK and Akt/Erk activation in our GOF Shp2-expressing myeloid cells 
(Figure 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 
 
 
Figure 5.1: Schematic of proposed signaling pathway explaining the ability of BTK to 
activate Akt and Erk in Shp2E76K/+;LysMcre+ myeloid cells 
We hypothesized that BTK phosphorylates BCAP, allowing BCAP binding to p85α and 
promotion of PI3K catalytic activity, thus leading to increased activation of Akt and Erk 
downstream. 
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Results 
Phosphorylation of the full-length BCAP isoforms is increased in response to GM-CSF 
stimulation and decreased by BTK inhibition in gain-of-function mutant Shp2E76K bone 
marrow-derived macrophages 
 In order to investigate if BCAP plays a role in connecting BTK to Akt/Erk in GOF 
Shp2-expressing myeloid cells, we first examined its activation in response to GM-CSF 
stimulation in bone marrow-derived macrophages from Shp2E76K/+;LysMcre+ mice. 
Because there is no commercially available anti-phospho-BCAP antibody, we used the 
strategy of pulling down total BCAP protein by immunoprecipitation, and then probing 
with an anti-phospho-tyrosine antibody. Based on the kinetics of Akt activation in 
mutant Shp2-expressing macrophages (Yang, Li 2008), we initially conducted these 
experiments using 1 hour of GM-CSF stimulation and saw no differences in BCAP 
phosphorylation compared to baseline (data not shown). We referred again to the 
paper describing the initial discovery of BCAP and saw that the authors found tyrosine 
phosphorylation to peak at 1 minute following BCR stimulation in DT40 chicken B cells, 
and then return to basal levels by 30 minutes (Okada, Maeda 2000). Therefore, we 
performed a time course experiment testing 10 minutes and 30 minutes of GM-CSF 
stimulation.  
After immunoprecipitation for BCAP and blotting for phospho-tyrosine, we 
observed the four isoforms corresponding to BCAP-S (BCAP1/BCAP2) and BCAP-L 
(BCAP3/BCAP4), as well as a larger band that potentially could be BCAP5 or BCAP6, 
which were previously reported to be less prevalent and not visible until after BCR 
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stimulation (Okada, Maeda 2000). In WT Shp2 macrophages, there was increased 
phosphorylation of both BCAP-S and BCAP-L isoforms at 10 minutes, with 
phosphorylation levels slightly decreased at 30 minutes (Figure 5.2, lanes 3, 4, and 5). 
However, in Shp2E76K-expressing macrophages, we saw a different pattern of baseline 
and GM-CSF-stimulated BCAP phosphorylation. Baseline BCAP phosphorylation was 
higher in the GOF Shp2-expressing cells compared to the WT Shp2-expressing cells, and 
following GM-CSF stimulation, phospho-BCAP was specifically increased in the full-
length isoforms (Figure 5.2, lanes 6, 7, and 8). In the mutant Shp2 myeloid cells, we also 
saw that phosphorylation peaked earlier at 10 minutes and somewhat decreased after 
30 minutes of GM-CSF stimulation. 
Our findings are consistent with those observed in DT40 chicken B cells that 
BCAP3/BCAP4 has five fold more tyrosine phosphorylation than BCAP1/BCAP2 following 
BCR stimulation (Okada, Maeda 2000). As mentioned previously, BCAP3/BCAP4 seem to 
be more important than BCAP1/BCAP2 for binding to and activating PI3K (Ni, 
MacFarlane 2012). Thus, our results imply that there may be more BCAP-induced 
activation of PI3K in macrophages expressing GOF Shp2 compared to WT Shp2. 
 Having seen that BCAP is activated in mutant Shp2-expressing macrophages, we 
next wanted to interrogate the BTK-to-BCAP signaling pathway. Based on the B cell 
signaling pathway, we hypothesized that BTK phosphorylates BCAP, which would allow 
binding to p85α and promotion of PI3K activity, thus activating Akt and Erk (Figure 5.1). 
To test the hypothesis that BCAP is a BTK substrate in GOF Shp2-expressing myeloid  
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Figure 5.2: BCAP phosphorylation is increased by GM-CSF stimulation specifically in 
the full-length isoforms in bone marrow-derived macrophages from 
Shp2E76K/+;LysMcre+ mice 
Bone marrow-derived macrophages expressing WT Shp2 or Shp2E76K were treated with 
10ng/mL of GM-CSF for 0, 10, or 30 minutes before lysing. Protein lysates were 
subjected to immunoprecipitation (IP) with anti-BCAP antibody followed by 
immunoblotting with anti-phospho-tyrosine. 390mg of protein lysis were loaded per 
lane and IP was performed with 5μg/mL of the anti-BCAP antibody. 
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cells, we used the BTK inhibitor ACP-196 to treat Shp2E76K-expressing macrophages that 
were stimulated with GM-CSF for 10 minutes. With 0.5μM and 1μM concentrations of 
ACP-196, we observed a dose-dependent decrease in BCAP phosphorylation, indicating 
that BTK is responsible for phosphorylating BCAP in GOF Shp2-expressing myeloid cells 
(Figure 5.3, lanes 3, 4, and 5). 
 
Total BCAP expression is increased in gain-of-function mutant Shp2-expressing 
macrophages compared to WT Shp2-expressing macrophages 
 Given the variable phosphorylation pattern of BCAP in GOF Shp2-expressing cells 
compared to WT Shp2-expressing cells, we investigated if total BCAP expression is also 
altered in mutant Shp2-expressing cells. We tested this by retrovirally transducing WT 
Shp2 or Shp2E76K tagged with GFP into bone marrow LDMNCs isolated from WT mice. 
GFP+ cells were sorted using fluorescence activated cell sorting and plated in media 
containing 25ng/mL of macrophage colony-stimulating factor to obtain macrophages 
expressing WT Shp2 or Shp2E76K. In both primary bone marrow-derived macrophages 
retrovirally transduced with Shp2E76K and primary bone marrow-derived macrophages 
isolated from Shp2E76K/+;LysMcre+ mice (data not shown), we found increased BCAP 
protein levels compared to WT Shp2-expressing control cells (Figure 5.4). 
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Figure 5.3: BCAP phosphorylation is decreased by ACP-196 in a dose-dependent 
manner in bone marrow-derived macrophages from Shp2E76K/+;LysMcre+ mice 
Bone marrow-derived macrophages expressing Shp2E76K were treated with 10ng/mL of 
GM-CSF for 10 minutes with 0μM, 0.5μM, or 1μM ACP-196 before lysing. Protein lysates 
were subjected to immunoprecipitation (IP) with anti-BCAP antibody followed by 
immunoblotting (IB) with anti-phospho-tyrosine. 650mg of protein lysis were loaded per 
lane and IP was performed with 5ug/mL of the anti-BCAP antibody. 
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Figure 5.4: BCAP expression is increased in bone marrow-derived macrophages 
expressing Shp2E76K 
Primary bone marrow low-density mononuclear cells were isolated from WT mice, 
transduced with either WT Shp2-GFP or Shp2E76K-GFP constructs, and sorted for GFP+ 
cells. The GFP+ cells were differentiated into macrophages and treated with or without 
10ng/mL of GM-CSF for 10 minutes before lysing. Immunoblot shows total BCAP levels 
with β-actin used as a loading control. 
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Mutagenesis of the SH2 domains of p85α leads to decreased interaction with BCAP in 
gain-of-function mutant Shp2-expressing cells 
 Next, we wanted to further investigate the interaction between BCAP and the 
p85α regulatory subunit of PI3K in GOF Shp2-expressing and WT Shp2-expressing cells.  
As mentioned previously, BCAP was first isolated by binding to the N-SH2 domain of 
p85α (Okada, Maeda 2000). However, studies have shown that the N-terminal and the 
C-terminal SH2 domains can both bind with high affinity to similar phospho-tyrosine 
sequences (Songyang, Shoelson 1993). In addition to examining potential differences in 
the interaction between p85α and BCAP in cells expressing GOF Shp2 and WT Shp2, we 
wanted to test if mutation of the p85α SH2 domains differentially affected the p85α-
BCAP interaction in GOF Shp2-expressing compared to WT Shp2-expressing cells. As the 
first step, we explored the consequences of complete loss of SH2 domain binding ability 
in the context of mutant or WT Shp2 expression. 
 To perform these experiments, we generated cell lines ectopically expressing 
p85α, Shp2, and BCAP. We utilized WT and mutant p85α plasmid constructs previously 
generated in our lab. These constructs were created by site-directed mutagenesis to 
render the p85α N-SH2 and C-SH2 domains unable to bind to phospho-tyrosine residues 
using the R358A and R649A mutations, respectively (Rordorf-Nikolic, Van Horn 1995, Yu, 
Wjasow 1998). These p85α mutant constructs were fused to yellow fluorescent protein 
(YFP) in order to track p85α expression. For Shp2 expression, we utilized previously 
generated Shp2 constructs (WT or E76K) that contain the neomycin resistance (neoR) 
cassette (Chan, Leedy 2005). Finally, we created a novel plasmid construct containing  
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Figure 5.5: Schematic of transduction strategy used to generate NIH3T3 cells 
expressing three proteins-of-interest: Shp2, p85α, and BCAP. 
Serial transduction and selection were performed to obtain NIH3T3 cells stably 
expressing WT Shp2 or Shp2E76K, WT or R358A/R649A p85α, and BCAP. Shp2 was 
selected for using neomycin-containing media, p85α was sorted for YFP positivity, and 
BCAP was sorted for mCherry positivity. 
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full-length BCAP in tandem with mCherry. In a stepwise fashion, we introduced the 
constructs into NIH3T3 cells followed by selection in order to generate the following 
stable cell lines: 1) WT Shp2, WT p85α, BCAP; 2) WT Shp2, R358A/R649A p85α, BCAP; 3) 
Shp2E76K, WT p85α, BCAP; and 4) Shp2E76K, R358A/R649A p85α, BCAP (Figure 5.5). We 
collected protein lysates from each of the exponentially growing cell lines and 
performed co-immunoprecipitation assays to compare the amount of p85α-BCAP 
interaction in GOF Shp2-expressing cells and WT Shp2-expressing cells.  
From these studies, we did not see a difference in the BCAP-p85α interaction 
between WT Shp2- and GOF Shp2-expressing cells (Figure 5.6A, compare lanes 2 and 4). 
In both the WT Shp2- and GOF Shp2-expressing cells, we found reduced interaction 
between BCAP and p85α in the cells expressing the double mutant R358A/R649A p85α 
construct compared to WT p85α (Figure 5.6A, compare lanes 2 and 3, and lanes 4 and 
5). A western blot on the same protein lysates demonstrated essentially equal 
quantification/loading of samples and consistent levels of expression in p85α and BCAP 
between the four cell lines, although the two samples with p85α R358A/R649A may 
have had slightly higher levels of the p85α construct compared to the WT p85α samples 
(Figure 5.6B). This confirms that BCAP contains the motifs necessary for binding to the 
SH2 domains of p85α and validates our cell model system for the use of studying this 
interaction. Future studies will include co-immunoprecipitation assays using the p85α 
SH2 domain single mutants. Any differences will tell us which (if either) of the two SH2 
domains are more vital for BCAP binding. 
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Figure 5.6: BCAP interaction with p85α is decreased by mutagenesis of both SH2 
domains 
(A) Protein lysates were collected from each of the stably expressing NIH3T3 cell lines 
and were subjected to immunoprecipitation (IP) with anti-p85α antibody followed by 
immunoblotting (IB) with anti-BCAP. 950mg of protein lysate was used for each IP using 
a 1:25 dilution of the anti-p85α antibody. (B) Western blots probing for p85α-YFP 
(~110kDa) or BCAP-mCherry (~130kDa) using lysates from each NIH3T3 cell line. 
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Discussion 
 From our initial biochemistry studies using a BTK inhibitor in GOF Shp2-
expressing macrophages, we found that BTK promotes Akt and Erk phosphorylation in a 
phospho-PLCγ2 independent manner (Chapter Four, Figure 4.2). Because PLCγ2 is 
known to be directly phosphorylated by BTK in B cells, which then promotes Erk 
activation, we addressed the unanswered question of how BTK signals to the 
downstream effectors Akt and Erk in GOF Shp2-expressing macrophages. Upon review 
of the literature on the BCR signaling pathway, we found that an alternative direct 
target of BTK is B cell adaptor for PI3K (BCAP). As its name suggests, BCAP is an adaptor 
protein that interacts with the p85α regulatory subunit of PI3K. BCAP contains three 
YxxM motifs that, once phosphorylated, can bind to p85α and enhance PI3K catalytic 
activity. As PI3K-to-Akt is a classical signaling pathway and PI3K is known to cross-talk 
with other pathways to promote Erk activation (Aksamitiene, Kiyatkin 2012), we 
hypothesized that BCAP phosphorylation may serve as a phospho-PLCγ2-independent 
means of BTK-induced hyperactivation of Akt and Erk in GOF Shp2-expressing 
macrophages. 
 First, to establish the importance of BCAP in bone marrow-derived macrophages 
expressing mutant Shp2, we measured the GM-CSF-stimulated phosphorylation of 
BCAP. We visualized the four isoforms of BCAP and saw increased pan-BCAP 
phosphorylation following GM-CSF in the WT Shp2 cells. However, in the Shp2E76K-
expressing macrophages, we saw increased phosphorylation specifically in BCAP3 and 
BCAP4 isoforms (Figure 5.2). This finding is intriguing because it has been previously 
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shown in macrophages that the full-length BCAP isoforms play a more important role in 
PI3K activation compared to the shorter isoforms. Ni et. al found that BCAP3/BCAP4 
were selectively phosphorylated and correspondingly led to increased interaction with 
p85α in cells lacking Syk expression. Additionally, although BCAP is predominantly found 
in the cytoplasm, once activated, it translocates to the plasma membrane, where it 
recruits PI3K to its lipid substrate. Ni et. al observed that the full length BCAP3/BCAP4 
isoforms, rather than the shorter BCAP1/BCAP2 isoforms, were preferentially 
phosphorylated and associated with the membrane fraction in LPS-stimulated 
macrophages (Ni, MacFarlane 2012). Thus, our finding that the larger BCAP isoforms are 
more hyper-phosphorylated in the GOF Shp2-expressing macrophages is consistent with 
these previous data indicating that activation of the two larger BCAP isoforms are 
responsible for PI3K activation. 
 Next, we tested if BTK activity leads to increased BCAP phosphorylation in 
myeloid cells. We had already found that the BCR signaling pathway is not faithfully 
reproduced in myeloid cells, as BTK inhibition does not reduce the phosphorylation of 
PLCγ2. This lack of an effect of BTK inhibition on PLCγ2 phosphorylation is either 
because PLCγ2 is not a BTK substrate in myeloid cells, or because an alternative pathway 
is upregulated that compensates for BTK inhibition. Therefore, verifying that BTK 
inhibition alters BCAP phosphorylation was crucial for implicating BCAP function in BTK 
signaling in myeloid cells. We used two different concentrations of the Acerta Pharma 
BTK inhibitor, ACP-196, and demonstrated a dose-dependent decrease in BCAP 
phosphorylation in Shp2E76K-expressing macrophages (Figure 5.3). This finding confirms 
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that BTK does signal to BCAP in myeloid cells as it does in B cells and strengthens the 
hypothesis that BCAP may connect BTK to Akt and Erk activation. Studies using the 
stably expressing NIH3T3 cell lines further confirmed that BCAP interacts with the 
regulatory subunit of PI3K, p85α, and that one or both of the p85α SH2 domains are 
necessary for the BCAP-p85α interaction. These data collectively support a signaling 
mechanism involving a positive feedback loop: PI3K activation of BTK via Plekstrin 
Homology domain binding to PI(3,4,5)P3, BTK phosphorylation of BCAP, phospho-BCAP 
interaction with p85α leading to PI3K catalytic activation, and subsequent augmentation 
of PI3K-dependent activation of BTK (Figure 5.1). Characterization of this signaling 
mechanism in GOF Shp2-expressing myeloid cells corroborates the biochemical and 
functional findings that dual p110δ and BTK inhibition works cooperatively in vitro and 
in vivo (Chapter Four) and validates the rationale for using this inhibitor strategy for the 
treatment of GOF Shp2-induced myeloid leukemia in order to simultaneously block two 
targets in this positive feedback loop. 
 We were initially surprised at the finding that there was no apparent increase in 
p85α-BCAP interaction in the Shp2E76K-expressing cells compared to the WT Shp2-
expressing cells (Figure 5.6). We expected to see increased interaction, which may 
account for increased BCAP stability and increased total BCAP expression found in cells 
expressing GOF Shp2 (Figure 5.4). However, these results were obtained from studies 
using NIH3T3 cells, a mouse fibroblast cell line, which does not express endogenous BTK 
or BCAP, as NIH3T3 are a non-hematopoietic cell line. Therefore, this model system 
lacks hyperactive BTK, which is needed to hyperphosphorylate BCAP and potentially 
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produce an enhanced interaction with p85α compared to WT Shp2 cells. To carry these 
studies forward, we will focus on the interaction of endogenous p85α and BCAP in WT 
Shp2- and GOF Shp2-expressing hematopoietic cells to determine if an increased 
interaction between BCAP and p85α may account for the increased total BCAP 
expression found in GOF Shp2-expressing macrophages (Figure 5.4). 
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CHAPTER SIX 
MICE WITH COMBINED MUTANT Shp2D61Y AND DNMT3A HAPLOINSUFFICIENCY HAVE 
RAPID DEVELOPMENT OF MYELOPROLIFERATIVE NEOPLASM 
Introduction 
 Loss of DNA methyltransferase 3A (DNMT3A) activity has been shown to lead to 
hematopoietic stem cell differentiation defects and the development of myeloid 
malignancies. DNMT3A is commonly mutated in myeloid diseases, with mutations found 
in over 20% of acute myeloid leukemia (AML) patients (Ley, Ding 2010). For AML 
patients, 60% of those with a DNMT3A mutation are heterozygous at Arginine 882 
(R882), a dominant negative mutation that results in less than 80% enzymatic activity 
(Kim, Zhao 2013). The remaining patients usually exhibit compound heterozygous or 
homozygous mutations. 
In contrast to AML, individuals with clonal hematopoiesis of indeterminate 
potential (CHIP) commonly bear a loss-of-function mutation in only one copy of 
DNMT3A (Xie, Lu 2014) and mutations in R882 are rare in this preleukemic state (Young, 
Challen 2016). These otherwise normal individuals are at an increased risk of developing 
MDS/AML due to acquisition of a second driver mutation (Jaiswal, Fontanillas 2014) and 
tend to have a poor overall prognosis (Ley, Ding 2010). Thus, although DNMT3A protein 
function must be almost completely lost in order to result in malignancy (Mayle, Yang 
2015), heterozygous loss-of-function mutations are often found combined with a driver 
mutation during the course of development of frank leukemia. Furthermore, Dnmt3a 
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haploinsufficiency alone with no other lesions is sufficient for mice to develop myeloid 
malignancies when aged to 18-24 months (Cole, Russler-Germain 2017). 
We studied the effects of Dnmt3a haploinsufficiency combined with Ptpn11D61Y, 
a gain-of-function mutation encoding oncogenic Shp2, which is the most commonly 
mutated gene in JMML (Chan, Kalaitzidis 2009). Concurrent mutations in both DNMT3A 
and PTPN11, albeit rare, have been reported in AML (Chen, Chen 2015, Hou, Kuo 2012) 
and in JMML patients (Stieglitz, Mazor 2017, Stieglitz, Taylor-Weiner 2015). Clinical 
outcomes in JMML vary considerably from spontaneous regression to rapid progression. 
In an effort to better predict prognosis and guide treatment strategies, Stieglitz et. al 
have shown that JMML cases with secondary mutations have much poorer prognosis 
and require aggressive treatment (Stieglitz, Taylor-Weiner 2015). The authors recently 
discovered that DNA methylation status of the genome is predictive of patient outcome 
as well (Stieglitz, Mazor 2017). Because of the need to better understand the 
mechanisms of disease in JMML, especially when involving alterations in DNA 
methylation, we studied the combined effects of Ptpn11 and Dnmt3a mutations in a 
mouse model of JMML. 
 
Results 
Dnmt3a+/-;D61Y double mutant mice have accelerated disease progression in comparison 
to control and single mutant mice 
We crossed Ptpn11D61Y/+;Mx1-cre+ mice (Chan, Kalaitzidis 2009) with Dnmt3a+/- 
mice (Yu, Zhou 2012) to produce Mx1-cre- (WT), Dnmt3a+/-;Ptpn11+/+;Mx1-cre+ 
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(Dnmt3a+/-), Dnmt3a+/+;Ptpn11D61Y/+;Mx1-cre+ (D61Y), and Dnmt3a+/-;Ptpn11D61Y/+;Mx1-
cre+ (Dnmt3a+/-;D61Y) mice. Six cohorts of mice, with 1 to 4 mice of each genotype, 
were treated with polyI:polyC to knockout one copy of Dnmt3a and to knock-in the 
mutant Ptpn11D61Y allele. All mice were followed until the Dnmt3a+/-;D61Y mice became 
moribund and the entire cohort was euthanized for analysis, which occurred at an 
average of 24 weeks after polyI:polyC treatment. We found that at the time when the 
Dnmt3a+/-;D61Y mice appeared moribund (thin, hunched, increased respiratory rate and 
effort, abdominal distension, ruffled fur, pale extremities), the Mx1-cre- or single mutant 
mice of the same cohort remained healthy. Upon euthanasia, the Dnmt3a+/-;D61Y mice 
showed obvious splenomegaly and the spleen to body weight percentage was 
significantly increased compared to the other three genotypes (Figure 6.1A). In addition 
to splenomegaly, the double mutant mice also showed significantly higher peripheral 
blood WBC counts compared to WT or Dnmt3a+/- mice (Figure 6.1B).  
 
Dnmt3a+/-;D61Y mice have increased myeloid cells in the periphery and increased 
granulocyte macrophage progenitors in the bone marrow 
Flow cytometric analysis of the spleen and peripheral blood to assess the 
frequency of Gr1+Mac1+ myeloid cells revealed a significantly higher percentage of these 
mature myeloid cells in the Dnmt3a+/-;D61Y mice compared to WT and Dnmt3a+/- mice 
in the spleen, and compared to WT mice in the peripheral blood (Figure 6.2 and 6.3). In 
contrast, the myeloid cell frequencies in the single mutant mice were not statistically 
different from WT mice except for D61Y mice in the peripheral blood (Figure 6.3A). The  
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Figure 6.1: Dnmt3a+/-;D61Y mice show splenomegaly and leukocytosis at the time of 
death 
(A) Average spleen to body weight ratio of mice at the time of euthanasia; n=13 for WT, 
n=9 for Dnmt3a+/-, n=10 for D61Y, n=6 for Dnmt3a+/-;D61Y, *p<0.0001 comparing 
Dnmt3a+/-;D61Y to WT, *p=0.003 comparing Dnmt3a+/-;D61Y to Dnmt3a+/-, *p=0.003 
comparing Dnmt3a+/-;D61Y to D61Y; statistical analyses performed by unpaired, two-
tailed, Student’s t-test. (B) Average WBC count in peripheral blood of mice immediately 
prior to euthanasia; n=8 for WT, n=7 for Dnmt3a+/-, n=5 for D61Y, n=5 for Dnmt3a+/-
;D61Y; *p=0.0157 comparing Dnmt3a+/-;D61Y to WT, *p=0.018 comparing Dnmt3a+/-
;D61Y to Dnmt3a+/-; statistical analyses performed by unpaired, two-tailed, Student’s t-
test. 
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Figure 6.2: Dnmt3a+/-;D61Y mice have increased Gr1+Mac1+ myeloid cells in the spleen 
at the time of death 
(A) Spleen average percentage of myeloid cells (Gr1+Mac1+) gated on live events and (B) 
representative flow diagrams; n=10 for WT, n=7 for Dnmt3a+/-, n=9 for D61Y, n=5 for 
Dnmt3a+/-;D61Y, *p=0.0095 comparing Dnmt3a+/-;D61Y to WT, *p=0.0177 comparing 
Dnmt3a+/-;D61Y to Dnmt3a+/-; statistical analyses performed by unpaired, two-tailed, 
Student’s t-test. 
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Figure 6.3: Dnmt3a+/-;D61Y mice have increased Gr1+Mac1+ myeloid cells in the 
peripheral blood at the time of death 
(A) Peripheral blood average percentage of myeloid cells (Gr1+Mac1+) gated on live 
events and (B) representative flow diagrams; n=12 for WT, n=9 for Dnmt3a+/-, n=9 for 
D61Y, n=5 for Dnmt3a+/-;D61Y, *p=0.0025 comparing Dnmt3a+/-;D61Y to WT, *p=0.0009 
comparing D61Y to WT; statistical analyses performed by unpaired, two-tailed, 
Student’s t-test. (C) Peripheral blood average absolute number of myeloid cells 
(Gr1+Mac1+) calculated by multiplying percentage and WBC count; n=12 for WT, n=9 for 
Dnmt3a+/-, n=9 for D61Y, n=5 for Dnmt3a+/-;D61Y, *p=0.0002 comparing Dnmt3a+/-;D61Y 
to WT, *p=0.0034 comparing Dnmt3a+/-;D61Y to Dnmt3a+/-, *p=0.0003 comparing D61Y 
to WT, *p=0.0159 comparing D61Y to Dnmt3a+/-; statistical analyses performed by 
unpaired, two-tailed, Student’s t-test. 
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Figure 6.4: Dnmt3a+/-;D61Y mice have decreased B cells and T cells in the periphery at 
the time of death 
(A) Spleen average percentage of B cells (CD19+ or B220+) and T cells (CD4+ or CD8+) 
gated on live events; n=13 for WT, n=9 for Dnmt3a+/-, n=9 for D61Y, n=6 for Dnmt3a+/-
;D61Y, *p=0.0386 comparing Dnmt3a+/-;D61Y to WT B cells, *p=0.0013 comparing 
Dnmt3a+/-;D61Y to WT T cells; statistical analyses performed by unpaired, two-tailed, 
Student’s t-test. (B) Peripheral blood average percentage of B cells (CD19+ or B220+) and 
T cells (CD4+ or CD8+) gated on live events; n=12 for WT, n=9 for Dnmt3a+/-, n=9 for 
D61Y, n=5 for Dnmt3a+/-;D61Y, *p=0.0071 comparing Dnmt3a+/-;D61Y to WT T cells; 
statistical analyses performed by unpaired, two-tailed, Student’s t-test. 
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absolute number of Gr1+Mac1+ cells were also significantly greater in double mutant 
mice relative to the WT and Dnmt3a+/- mice (Figure 6.3C). In contrast to the increase in 
myeloid cells, the T and B cells were decreased in the spleen and peripheral blood of 
Dnmt3a+/-;D61Y mice relative to other groups (Figure 6.4A and 6.4B). 
In an effort to explain the increase in mature myeloid cells in the double mutant 
mice, we performed flow cytometric analysis on bone marrow cells from all four 
genotypes to assess the number of granulocyte macrophage progenitors (GMPs). As 
seen in Figure 6.5, Dnmt3a+/-;D61Y mice showed a significant increase in the absolute 
number of GMPs compared to WT and Dnmt3a+/- mice. The double mutant mice also 
had significantly more absolute numbers of megakaryocyte erythrocyte progenitors 
(MEPs) compared to WT mice, but no significant differences in common myeloid 
progenitors (CMPs) were observed among any of the four groups (Figure 6.5). 
 
Dnmt3a+/-;D61Y mice have signs of anemia and increased erythroid progenitors in the 
spleen 
The double mutant mice also showed signs of anemia, with significant decreases 
in peripheral red blood cell counts, hemoglobin levels, as well as hematocrits relative to 
WT mice (Figure 6.6). Consistent with these observations, within the erythroid lineage, 
the CD36+CD71+ erythroid progenitors (EPs) were significantly increased in the spleens 
of the Dnmt3a+/-;D61Y mice, suggesting compensatory erythropoiesis (Figure 6.7). 
Although EP frequency was not increased in the Dnmt3a+/-;D61Y bone marrow  
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Figure 6.5: Dnmt3a+/-;D61Y mice have increased GMPs and MEPs in the bone marrow 
at the time of death 
(A) Absolute numbers of granulocyte monocyte progenitors (GMPs), common myeloid 
progenitors (CMPs), and megakaryocyte erythrocyte progenitors (MEPs) in bone 
marrow, gated on lineage-cKit+Sca1- events and (B) representative flow diagrams; n=10 
for WT, n=6 for Dnmt3a+/-, n=6 for D61Y, n=4 for Dnmt3a+/-;D61Y, *p=0.0159 comparing 
Dnmt3a+/-;D61Y GMPs to WT GMPs, *p=0.0445 comparing Dnmt3a+/-;D61Y GMPs to 
Dnmt3a+/- GMPs, *p=0.0186 comparing Dnmt3a+/-;D61Y MEPs to WT MEPs; statistical 
analyses performed by unpaired, two-tailed, Student’s t-test. 
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Figure 6.6: Dnmt3a+/-;D61Y mice have anemia as indicated by peripheral blood 
measurements immediately prior to euthanasia 
(A) Average peripheral blood red blood cell (RBC) count in mice immediately prior to 
euthanasia; n=8 for WT, n=7 for Dnmt3a+/-, n=5 for D61Y, n=5 for Dnmt3a+/-;D61Y, 
*p=0.0005 comparing Dnmt3a+/-;D61Y to WT. (B) Average peripheral blood hemoglobin 
values in mice immediately prior to euthanasia; n=8 for WT, n=6 for Dnmt3a+/-, n=5 for 
D61Y, n=5 for Dnmt3a+/-;D61Y, *p=0.0002 comparing Dnmt3a+/-;D61Y to WT, *p=0.0016 
comparing Dnmt3a+/-;D61Y to Dnmt3a+/-. (C) Average peripheral blood hematocrit 
values in mice immediately prior to euthanasia; n=8 for WT, n=7 for Dnmt3a+/-, n=5 for 
D61Y, n=5 for Dnmt3a+/-;D61Y, *p=0.001 comparing Dnmt3a+/-;D61Y to WT, statistical 
analyses performed by unpaired, two-tailed, Student’s t-test.  
 
 
 
 
125 
 
 
Figure 6.7: Dnmt3a+/-;D61Y mice have compensatory erythropoiesis in the spleen 
(A) Average percentage of erythroid progenitors (CD36+CD71+) in spleen gated on live 
events, with (B) representative flow diagrams; n=6 for WT, n=4 for Dnmt3a+/-, n=3 for 
D61Y, n=3 for Dnmt3a+/-;D61Y; *p=0.0177 comparing Dnmt3a+/-;D61Y to WT, statistical 
analyses performed by unpaired, two-tailed, Student’s t-test. 
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compartment (data not shown), the increased splenic erythropoiesis may explain the 
increased bone marrow MEP numbers. 
Discussion 
Individuals with CHIP often have partial loss of DNMT3A enzyme activity, but 
how this affects the development and progression of leukemia when combined with a 
second driver mutation is not known. We observed that mice with heterozygous loss of 
Dnmt3a combined with a gain-of-function Shp2 mutation, D61Y, develop more rapid 
disease progression and earlier mortality. Mice expressing Shp2D61Y do not usually 
succumb to leukemia until 45 weeks after induction of expression (Chan, Kalaitzidis 
2009) and mice with Dnmt3a haploinsufficiency not develop disease until approximately 
80 weeks (Cole, Russler-Germain 2017). We found that mice with the two mutations 
together become moribund much earlier at 24 weeks, indicating that they cooperate to 
promote myeloid leukemia progression and to shorten survival.  
The most marked phenotypic changes we observed in the Dnmt3a+/-;D61Y mice 
were splenomegaly, mature myeloid cell expansion in the periphery, as well as 
increased GMPs in the bone marrow. These mice also exhibited signs of anemia, 
perhaps due to defects in erythrocyte cell maturation in the bone marrow. In support of 
this notion, MEPs in the bone marrow of compound mutant mice were increased and 
there were more erythroid progenitors present in the spleen, which most likely 
contributed to the splenomegaly in these mice. 
The disease course of JMML also exhibits pronounced splenomegaly, sometimes 
even in the absence of highly elevated WBC count. It has been previously reported that 
127 
mice with Dnmt3a-/- combined with KrasG12D/+ mutation, another common mutation 
found in JMML patients, developed stress erythropoiesis in the spleen (Chang, You 
2015). Perhaps one reason JMML patients develop extreme splenomegaly is 
compensatory splenic erythropoiesis, as observed in the Dnmt3a+/-;D61Y mice in this 
study.  
Because DNMT3A and PTPN11 mutations are found in combination in AML and 
JMML patients, our double mutant mice provide a novel clinically relevant model for 
developing and evaluating therapies for myeloid leukemia. In AML, the presence of a 
DNMT3A mutation led to significantly shortened overall survival (Ley, Ding 2010). For 
JMML, a disease with poor prognosis, there is currently no established decision-making 
process for determining which patients would be candidates for experimental therapies. 
However, it is known that the number of mutations present at diagnosis is strongly 
correlated with survival when comparing patients who have 0-1 mutations to those with 
2 or more mutations (Stieglitz, Taylor-Weiner 2015). Further work must be done to find 
the importance of having specifically the DNMT3A and PTPN11 genes mutated together, 
but these are two commonly mutated genes in myeloid leukemia that we have now 
shown leads to accelerated disease.  
The mechanism of how Dnmt3a loss cooperates with driver mutations to 
accelerate disease progression is still unknown, but this Dnmt3a+/-;D61Y mouse model 
will be useful to explore this question. Perhaps the changes in methylation caused by 
reduced DNMT3A activity lead to epigenetic changes that alter the normal transcription 
of tumor suppressor genes needed to dampen Shp2 signaling. Future work performing a 
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genome-wide transcriptional analysis would help to elucidate the mechanism of 
enhanced myeloid leukemia observed in the double mutant mice. 
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CHAPTER SEVEN 
DISCUSSION 
 Juvenile myelomonocytic leukemia (JMML) is a disease with a poor prognosis 
that urgently needs effective therapies. There are currently no chemotherapies that can 
improve overall or event-free survival, and allogeneic hematopoietic stem cell 
transplant has high therapy-induced morbidity as well as a high relapse rate of 50% (Loh 
2011). SHP2 is the most commonly mutated protein in JMML patients, with gain of 
function (GOF) mutations in PTPN11 making up 35% of all cases (Chan, Cooper 2009). 
One of the classic features of JMML is progenitor hypersensitivity to GM-CSF with 
hyperactivation of the RAS/MAPK signaling pathway.  However, our laboratory has 
shown that the PI3K/AKT pathway is also important, since AKT (as well as ERK) is hyper-
phosphorylated in GOF Shp2 cells after GM-CSF stimulation. Importantly, our lab also 
found that p110δ is a hematopoietic-specific PI3K catalytic subunit that promotes GOF 
Shp2-induced leukemia (Goodwin, Li 2014). These studies were done using genetic 
inactivation of Pik3cd and p110δ-specific pharmacologic inhibition in vitro, and we 
wanted to take the next step in making these findings applicable to JMML patients by 
performing in vivo pharmacologic studies. 
 We treated Shp2E76K/+;LysMcre+ mice with the specific and potent p110δ 
inhibitor, GS-9820, and found significantly reduced splenomegaly and prolonged survival 
compared to the vehicle-treated controls (Figures 3.1 and 3.8), indicating that the 
reduced activation of Akt and Erk and the reduced cell hyperproliferation observed in 
vitro translates into substantial improvements in vivo. We also found that there were 
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significantly decreased phenotypically-defined progenitor cells in the bone marrow 
(Figure 3.3) and a corresponding increase in mature myeloid cells in the peripheral 
blood (Figure 3.6), suggesting that inhibition of p110δ induces myeloid differentiation. 
Having demonstrated that p110δ inhibition can treat GOF Shp2-induced 
leukemia, we next wanted to further the therapeutic impact of our findings by 
identifying other signaling molecules that cooperate with p110δ to promote Shp2 
signaling. Because mechanisms of cancer resistance include upregulation of 
downstream molecules and compensatory pathways, single-agent chemotherapy is 
unlikely to be effective in JMML patients. We observed this in our GS-9820-treated 
mice, as they eventually became moribund and succumbed to the same disease as their 
vehicle-treated counterparts (Figures 3.10-3.12). Thus, we decided to study downstream 
molecules in the p110δ signaling pathway that might be able to compensate for loss of 
p110δ activity. We identified Bruton’s tyrosine kinase (BTK) as a molecule-of-interest 
because it is known in B cell receptor (BCR) signaling to become activated downstream 
of PI3K. Ibrutinib, the first BTK inhibitor, obtained accelerated FDA approval and BTK has 
recently emerged in the field of lymphoid malignancies as a very successful therapeutic 
target for a variety of B cell malignancies.  
We used a second-generation BTK inhibitor, acalabrutinib (ACP-196), and 
another specific p110δ inhibitor, ACP-319, to explore the role that BTK plays in a GOF 
Shp2-induced myeloid leukemia. Our results showed that, while BTK inhibition alone 
failed to reduce proliferation of GOF Shp2-expressing cells, dual inhibition of BTK and 
p110δ cooperatively decreased the phosphorylation of Akt and Erk in bone marrow-
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derived macrophages from mutant Shp2-expressing mice and cooperatively decreased 
the hyperproliferation of cells stimulated with GM-CSF (Figure 4.3 and 4.4). In vivo, we 
initially used 15mg/kg doses of each drug and saw promising yet statistically 
insignificant trends in prolonged survival, decreased splenomegaly, and decreased 
peripheral blood WBC counts (Figures 4.5, 4.7, and 4.8). However, when we increased 
the dosing to 20mg/kg for each drug, we observed highly significant reductions in spleen 
size and leukocytosis (Figures 4.10 and 4.11). Similar to the study we performed using 
the p110δ inhibitor alone, the treated mice ultimately died of the same leukemia as the 
vehicle-treated mice (Figure 4.6 and data not shown). Thus, the drug treatment would 
need to be continued beyond the 21 days in order to obtain a sustained effect. The 
dosing regimen likely could be decreased from twice per day to once per day or less 
during this maintenance phase to attain prolonged suppression of myeloproliferation. 
Similar to our GS-9820 study, we also observed fewer phenotypically-defined 
progenitors in the bone marrow and more terminally differentiated myeloid cells in the 
peripheral blood in mice treated with dual BTK and p110δ inhibition (Figures 4.12 and 
4.15). Again, this finding implies that the combination of BTK and p110δ inhibition 
disrupts the tumor cell niche in the bone marrow and promotes myeloid cell 
maturation. This observation is consistent with what is seen in lymphoid diseases, 
where ibrutinib has disruptive effects on the tumor microenvironment and promotes 
peripheral distribution of the lymphoid leukemia cells due to BTK being an integral 
component of chemokine receptor signaling and supporting B cell homing to the lymph 
nodes and spleen. 
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The lack of efficacy observed with the BTK inhibitor alone may be due to TEC 
being able to compensate for BTK loss in mice (Ellmeier, Jung 2000). Ellmeier et. al 
generated Tec-/-Btk-/- mice and compared their phenotype to Btk-/- mice, concluding that 
TEC worked together with BTK to allow for normal B cell development. The authors 
postulated that the ability of TEC to partially compensate for BTK could explain the 
differences between X-linked immunodeficiency (XID) in mice and X-linked 
agammaglobulinemia (XLA) in humans. Both XID and XLA are due to loss-of-function 
mutations in Btk and BTK, respectively, but the murine XID has less severe B cell 
depletion (Cancro, Sah 2001). Therefore, it is possible that the use of ACP-196 in 
patients with myeloid diseases will show a superior response compared to that 
observed in mice because humans seemingly have a higher reliance on BTK signaling. 
 Next, we wanted to further explore the mechanism of BTK signaling in myeloid 
cells. Our biochemistry data had shown that PLCγ2 is not essential for BTK-dependent 
activation of Erk (Figures 4.2 and 4.3). We were intrigued by this observation, as it 
implied that BTK signals to Erk in myeloid cells in a phospho-PLCγ2-independent manner 
and in a fashion distinct from that described in BCR signaling. However, an alternative 
BTK downstream target that activates PI3K in B cells is B cell adaptor for PI3K (BCAP). 
We wanted to test if BCAP could be the connector between BTK and PI3K, thus leading 
to Akt and Erk activation (Figure 5.1). We performed immunoprecipitation assays to pull 
down total BCAP in bone marrow-derived macrophages and immunoblotted for 
phospho-tyrosine. In response to GM-CSF stimulation, there was selective 
phosphorylation of the two full-length BCAP isoforms in the Shp2E76K-expressing cells 
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(Figure 5.2). These are the BCAP isoforms previously defined to be more important for 
binding to and recruitment of PI3K to the plasma membrane, suggesting that GOF Shp2-
expressing cells have more BCAP-induced activation of PI3K. We also showed that 
treatment with ACP-196 reduced the phosphorylation of BCAP in a dose-dependent 
manner, suggesting that BTK-to-BCAP signaling is intact in macrophages (Figure 5.3). In 
order to study the mechanism of p85α-BCAP interaction, we used p85α constructs with 
specific sites mutated in the N-SH2 and C-SH2 domains to ablate the ability to bind to 
phospho-tyrosine residues. We transduced these p85α constructs, along with Shp2 and 
BCAP constructs, into NIH3T3 cells to study their interactions. We found that, compared 
to WT, the mutated p85α constructs had less binding to BCAP, confirming that BCAP 
binds to the SH2 domains of p85α (Figure 5.6). This gives more insight into the 
mechanism of BCAP-p85α interaction and informs on a strategy to potentially disrupt 
this binding. 
 Finally, we explored the consequences of combining a GOF Shp2D61Y mutation 
with heterozygous loss of Dnmt3a. JMML patients with more than one mutation have 
significantly poorer survival, and our mouse model reflects this observation as the 
double mutant mice became moribund at only 24 weeks of age with a 
myeloproliferative neoplasm. In comparison to control and single mutant mice, the 
Dnmt3a;D61Y mice had increased splenomegaly and leukocytosis (Figure 6.1), myeloid 
expansion in the spleen and peripheral blood (Figures 6.2 and 6.3), and more 
granulocyte macrophage progenitors (GMPs) in the bone marrow (Figure 6.5). We also 
observed a novel phenotype of defective erythrocyte differentiation, which led to 
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anemia in the Dnmt3a;D61Y mice with significantly reduced red blood cell count, 
hemoglobin, and hematocrit levels (Figure 6.6). In response, we observed evidence of 
compensatory erythropoiesis, as there was an increased proportion of erythroid 
progenitors in the spleens of the double mutant mice (Figure 6.7). DNMT3A is one of the 
first genes mutated in the development of preleukemia, and loss-of-function in HSCs 
leads to increased self-renewal and expansion of the mutated stem cells. JMML patients 
bearing secondary mutations, such as having mutated DNMT3A in addition to a PTPN11 
mutation, have a much poorer prognosis. It is still unknown how DNMT3A loss can cause 
enhanced disease in the context of GOF SHP2. One possibility is that the altered 
methylation pattern leads to aberrant repression of tumor suppressor genes and/or 
increased expression of oncogenes. We have shown that the Dnmt3a;D61Y mice exhibit 
the phenotype of accelerated leukemia and can be used as a model for the investigation 
of the mechanism of DNMT3A. 
 
Overall Conclusions and Significance 
 Juvenile myelomonocytic leukemia (JMML) is a rare childhood leukemia that 
urgently needs better therapies. Gain-of-function mutations in PTPN11, which encodes 
for the protein tyrosine phosphatase SHP2, are the most frequent mutations found in 
JMML patients. Downstream of SHP2 signaling, PI3K/AKT has recently been recognized 
to be as important as the RAF/MEK/ERK pathway for promoting leukemogenesis, 
particularly the hematopoietic-specific subunit p110δ (Goodwin, Li 2014). However, 
because single-agent cancer therapy is limited by resistance development, as evidenced 
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by the example of imatinib (Reddy and Aggarwal 2012), we looked for other signaling 
molecules that cooperate with p110δ to promote GOF Shp2 signaling. Lymphoid 
malignancy studies have demonstrated that Bruton’s tyrosine kinase (BTK) is a key 
player in cancer, with the inhibitor ibrutinib having much success recently in a variety of 
B cell lymphomas and leukemias. BTK may soon make the leap into the myeloid 
malignancies field as an important target. A study done in acute myeloid leukemia 
(AML) showed that BTK is constitutively phosphorylated in a majority of AML patient 
samples and that ibrutinib has good efficacy against AML blast proliferation in vitro 
(Rushworth, Murray 2014). 
Our studies here in GOF Shp2-expressing myeloid cells suggest that BTK has a 
significant role in myeloid malignancies as well. We used ACP-196, a second-generation 
inhibitor with less off-target binding than ibrutinib, to show that BTK inhibition 
cooperates with p110δ inhibition to reduce Akt/Erk hyperphosphorylation and 
hyperproliferation in response to GM-CSF. The dual inhibition also proved effective in 
vivo, with a significant decrease in splenomegaly and leukocytosis, and (with lower drug 
doses) trends towards prolonged survival. These experiments were done in mice with 
mutant Shp2 under the control of the lysozyme 2 promoter, limiting the expression 
specifically to the myeloid cells. These findings provide the first evidence that BTK 
inhibition can be effective as a combination treatment with p110δ inhibition to treat 
mutant Shp2-induced myeloproliferative neoplasm (MPN). It is also significant to note 
that we used Shp2E76K/+;LysMcre+ mice for both the single-agent p110δ inhibitor 
experiment and for the drug combination experiment. We observed a similar response 
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in both groups of treated mice, but the dose we used to obtain a response was less in 
the drug combination (20mg/kg) than the single-therapy p110δ inhibitor (30mg/kg). 
 The effect of BTK inhibition on the microenvironment is also relevant to our 
findings. Despite the significant effect of the two-inhibitor combination, we did not see 
any improvement for ACP-196 alone. Thus, perhaps the mechanism of ACP-196 in vivo is 
to disrupt the nurturing tumor microenvironment, as ibrutinib does in chronic 
lymphocytic leukemia (CLL) patients. By doing so, the leukemic cells are more vulnerable 
and susceptible to the effects of the p110δ drug. The microenvironment of JMML 
patients is suspected to be abnormal because of the high relapse rate after 
hematopoietic stem cell transplant. A recent paper also found that having a GOF Ptpn11 
mutation expressed in the bone marrow’s non-hematopoietic microenvironmental cells 
alone was sufficient for mice to fully develop MPN (Dong, Yu 2016). Therefore, testing 
microenvironment-altering drugs may be a new strategy worth pursuing for JMML. 
An alternative explanation for the lack of effect with BTK inhibition alone can be 
seen from our proposed signaling pathway. We show evidence that BTK may form a 
positive feedback loop with PI3K by way of B cell adaptor for PI3K (BCAP). Because PI3K 
is hyperactivated due to GOF Shp2 (Goodwin, Li 2014), inhibiting BTK alone is not 
sufficient to reduce this high level of p110δ activity. However, once p110δ activity is 
curtailed by the inhibitor ACP-319, PI3K may be more dependent on BTK 
phosphorylation of BCAP for recruitment to the cell membrane and continued 
activation. Therefore, the addition of a BTK inhibitor can now make a significant 
difference on the phosphorylation of downstream effectors and cell hyperproliferation. 
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The idea that BTK may be part of a positive feedback loop by way of BCAP 
phosphorylation to promote PI3K and its own activation gives some insight into the 
mechanism of action of the dual inhibition of BTK and p110δ. 
Our finding that full length BCAP (BCAP-L) is more important than shortened 
BCAP (BCAP-S) for activating PI3K may be explained by the BCAP protein structure. 
Perhaps the Toll-IL-1 receptor (TIR) domain at the N-terminal end of BCAP-L, which is 
absent from BCAP-S, allows BCAP-L to better associate with p85α and recruit PI3K to the 
plasma membrane. Toll-like receptor (TLR) signaling is known to activate PI3K, which 
then inhibits proinflammatory events and thus negatively regulates TLR signaling as a 
negative feedback loop (Hazeki, Nigorikawa 2007). It is known that BCAP-S cannot 
negatively regulate inflammation because it lacks the TIR domain. In fact, BCAP-S is a 
positive regulator of inflammation, so perhaps the TIR domain is necessary in order to 
bind to PI3K (Matsumura, Oyama 2010). Furthermore, in response to lipopolysaccharide 
(LPS), an activator of TLR signaling, there is increased tyrosine-phosphorylated BCAP at 
the membrane. Therefore, TLR signaling either phosphorylates BCAP already present at 
the membrane, or it causes translocation of the constitutively phosphorylated BCAP in 
the cytoplasm to the membrane (Ni, MacFarlane 2012). Thus, it seems that the TIR 
domain may be important for membrane recruitment of PI3K as well. 
A case report was recently published that strengthens the idea that BTK and PI3K 
are two intimately linked signaling partners. BTK loss causes X-linked 
agammaglobulinemia, but in this referenced case, a child was diagnosed with autosomal 
recessive agammaglobulinemia (Tang, Upton 2017). Rather than a loss-of-function 
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mutation in BTK, the patient had homozygous mutations in the PIK3R1 gene, which 
encodes p85α. This observation suggests that p85α is a crucial component of BTK 
signaling, as the complete loss of p85α phenocopies the complete loss of BTK. 
Finally, our results from crossing Dnmt3a+/- and D61Y mice provides further 
proof that multiple mutations lead to a more aggressive disease, consistent with that 
observed in JMML patients (Stieglitz, Taylor-Weiner 2015). Although the prognosis of 
JMML patients is variable, it is now known that secondary mutations and 
hypermethylation states are associated with poorer survival. Even though mutations in 
DNMT3A are loss-of-function and lead to hypomethylation of focal CpG sites, Stieglitz 
et. al found that all JMML patient samples bearing secondary mutations were globally 
hypermethylated (Stieglitz, Mazor 2017). It remains unknown why some JMML patients 
experience spontaneous resolution while others relapse soon after allogeneic HSCT. 
Perhaps the reason some patients relapse following transplantation is due to 
incomplete ablation of HSCs bearing DNMT3A mutations. These HSCs have been shown 
in mice to have increased self-renewal and will out-compete the normal donor HSCs 
(Challen, Sun 2011). If the leukemic clone in a JMML patient had acquired both mutant 
PTPN11 and DNMT3A, then this stem cell would expand even after allogeneic HSCT. 
Perhaps the addition of azacitidine or another hypomethylating agent to the treatment 
regimen would be beneficial to patients. 
To summarize, we have proposed and provided evidence that p110δ and BTK 
form a positive feedback loop with BCAP to drive their own activity and promote GOF 
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Shp2-induced leukemogenesis. We have also shown that the dual inhibition of p110δ 
and BTK is more effective than inhibition with either alone. 
 
Future Directions 
An important future experiment is to determine if BCAP knockdown leads to 
reduced phosphorylation of Akt and Erk in myeloid cells, which would cement the link 
between BCAP and these downstream effectors. To begin work on this, we have 
transduced BCAP shRNA into bone marrow low-density mononuclear cells expressing 
Shp2E76K. We are testing which shRNA results in the best knockdown of BCAP. Once this 
experimental model is optimized, we will use immunoblotting to look at phospho-Akt 
and phospho-Erk, and [3H]-thymidine assays to measure cell proliferation. If BCAP is 
indeed responsible for connecting BTK to PI3K, then we expect to see a reduction in all 
of these measures upon knockdown of BCAP expression. 
We will also continue our work on the mechanism of BCAP-p85α interaction. We 
already have a validated system in NIH3T3 cells in which we have shown that p85α 
constructs with both SH2 domains mutated have decreased BCAP binding. The next step 
is to test the effect of single SH2 domain mutations on the interaction. Because only the 
N-SH2 domain has been previously shown to bind to BCAP, we may find that mutating 
the C-SH2 domain has no effect. However, it is believed that both SH2 domains can bind 
to similar phospho-tyrosine sequences, so it is more likely that we will find each domain 
to be involved in BCAP binding, although we do not know to what degree. This would be 
vital information were we to attempt to disrupt the BCAP-PI3K binding in the future. 
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Another important question is whether other driver mutations of JMML also rely 
on p110δ and BTK to the same extent as Shp2E76K-induced JMML. We have focused our 
attention on the Shp2E76K/+;LysMcre+ mice, as PTPN11 is the most frequent mutation in 
patients and this mouse model is conducive to in vivo studies because of its consistent 
disease development. However, another 65% of JMML cases involve mutations in other 
genes, including KRAS, NF1, and CBL. Mouse models using these other driver genes 
could be used to repeat the same in vitro, and perhaps the in vivo, studies that we have 
shown here. This would potentially expand the applicability of our findings to more 
JMML patients and may bring the utility of p110δ and BTK inhibitors to other myeloid 
malignancies as well. 
Thus far, our work has been a purely pharmacologic approach. Although this is 
more realistic to patient situations than genetic studies, a genetically modified mouse 
lacking BTK or BCAP would provide results without the potential confounding off-target 
effects. Therefore, we predict that crossing GOF Shp2 mice with Btk-/- and the kinase-
dead p110δD910A/D910A mice would yield an even stronger cooperative effect on the 
correction of leukemia. A Pik3ap1-/- mouse would also prove very useful to demonstrate 
BCAP’s involvement in the BTK/PI3K signaling pathway. 
Finally, many questions remain unanswered about how Dnmt3a loss in mice 
expressing GOF Shp2 leads to accelerated leukemia development. One important 
experiment is to perform a genome-wide transcriptional analysis, which would clarify if 
the aberrant methylation due to mutant Dnmt3a directly affects Shp2 signaling. Two 
possible epigenetic consequences of loss of DNMT3A activity are that signaling 
141 
molecules upstream or downstream of Shp2 are upregulated, or that there is 
downregulation of proteins normally needed to dampen Shp2 signaling. An in vivo study 
including azacitidine in the treatment of Dnmt3a+/-;D61Y mice, perhaps in combination 
with a p110δ and/or BTK inhibitor, would further elucidate the role of DNMT3A in the 
progression of JMML and other myeloid malignancies. 
The results of our experiments show that the combined inhibition of p110δ and 
BTK effectively reduces the leukemia progression of GOF Shp2-induced JMML. Targeting 
both proteins at once is likely effective because it interrupts the positive feedback loop 
that they form with BCAP. It also allows a lower dose of each drug to be used compared 
to a single-agent p110δ inhibitor. These observations expand the role of BTK beyond B 
cell lymphoid malignancies into myeloid leukemia. In this regard, the p110δ/BTK dual 
inhibition strategy may be useful in conjunction with a methylating agent and in a 
variety of other malignancies as well. 
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